



## Clinical trial results:

**A phase II observer blind, randomised, controlled study to evaluate the safety, reactogenicity and immunogenicity of GSK Biologicals' candidate tuberculosis vaccine GSK 692342 when administered to adults aged 18 to 59 years with TB disease.**

### Summary

EudraCT number	2012-001820-36
Trial protocol	EE
Global end of trial date	10 April 2014

### Results information

Result version number	v2 (current)
This version publication date	19 March 2016
First version publication date	22 May 2015
Version creation reason	<ul style="list-style-type: none"><li>• New data added to full data set</li></ul> Data for secondary endpoints have been added.

### Trial information

#### Trial identification

Sponsor protocol code	114886
-----------------------	--------

#### Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	-
WHO universal trial number (UTN)	-

Notes:

### Sponsors

Sponsor organisation name	GlaxoSmithKline Biologicals
Sponsor organisation address	Rue de l'Institut 89, Rixensart, Belgium, B-1330
Public contact	Clinical Disclosure Advisor, GlaxoSmithKline Biologicals, 44 2089904466, GSKClinicalSupportHD@gsk.com
Scientific contact	Clinical Disclosure Advisor, GlaxoSmithKline Biologicals, 44 2089904466, GSKClinicalSupportHD@gsk.com

Notes:

### Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

## Results analysis stage

Analysis stage	Interim
Date of interim/final analysis	20 March 2015
Is this the analysis of the primary completion data?	Yes
Primary completion date	10 April 2014
Global end of trial reached?	Yes
Global end of trial date	10 April 2014
Was the trial ended prematurely?	Yes

Notes:

## General information about the trial

Main objective of the trial:

To assess the safety and reactogenicity of GSK Biologicals' candidate TB vaccine M72/AS01E in the study population.

Protection of trial subjects:

All subjects were supervised after vaccination/product administration with appropriate medical treatment readily available. Vaccines were administered by qualified and trained personnel. Vaccines were administered only to eligible subjects that had no contraindications to any components of the vaccines.

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	14 November 2011
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	No

Notes:

## Population of trial subjects

### Subjects enrolled per country

Country: Number of subjects enrolled	Estonia: 36
Country: Number of subjects enrolled	Taiwan: 106
Worldwide total number of subjects	142
EEA total number of subjects	36

Notes:

### Subjects enrolled per age group

In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	142
From 65 to 84 years	0
85 years and over	0

## Subject disposition

### Recruitment

Recruitment details: -

### Pre-assignment

Screening details:

During the screening the following was performed: informed consent was obtained and signed from parents or guardians of subjects, check for inclusion/exclusion criteria and contraindications/precautions was performed, and medical history of subjects was collected. Prior to vaccination, subjects' pre-vaccination body temperature was evaluated.

### Period 1

Period 1 title	Overall study (overall period)
Is this the baseline period?	Yes
Allocation method	Randomised - controlled
Blinding used	Double blind
Roles blinded	Subject, Investigator, Monitor, Carer

Blinding implementation details:

During the course of the study, the vaccine recipient and those responsible for the evaluation of any study endpoints have been unaware of which vaccine was administered.

### Arms

Are arms mutually exclusive?	Yes
<b>Arm title</b>	TB Treatment GSK 692342 Group

Arm description:

Subjects having completed the intensive phase of treatment, i.e. 2 to 4 months post initiation of treatment, who received the GSK 692342 vaccine according to a 2-dose schedule at Months 0 and 1.

Arm type	Experimental
Investigational medicinal product name	GSK 692342
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Injection
Routes of administration	Intramuscular use

Dosage and administration details:

Two doses of vaccine were administered intramuscularly in the deltoid region of the arm, on a 0, 1 Months schedule

<b>Arm title</b>	TB Treatment Saline Group
------------------	---------------------------

Arm description:

Subjects having completed the intensive phase of treatment, i.e. 2 to 4 months post initiation of treatment who received a placebo (physiological saline) according to a 2-dose schedule at Months 0 and 1.

Arm type	Placebo
Investigational medicinal product name	Physiological Saline
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Injection
Routes of administration	Intramuscular use

Dosage and administration details:

Doses were administered intramuscularly in the deltoid of the arm at Months 0 and 1

<b>Arm title</b>	TB Treated GSK 692342 Group
------------------	-----------------------------

Arm description:

Subjects having successfully completed treatment for TB disease at least 1 year prior to the study, who during this study received the GSK 692342 vaccine according to a 2-dose schedule at Months 0 and 1

Arm type	Experimental
Investigational medicinal product name	GSK 692342
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Injection
Routes of administration	Intramuscular use

**Dosage and administration details:**

Two doses of vaccine were administered intramuscularly in the deltoid region of the arm, on a 0, 1 Months schedule

<b>Arm title</b>	TB Treated Saline Group
------------------	-------------------------

**Arm description:**

Subjects having successfully completed treatment for TB disease at least 1 year prior to the study, who in this study received a placebo (physiological saline) according to a 2-dose schedule at Months 0 and 1.

Arm type	Placebo
Investigational medicinal product name	Physiological Saline
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Injection
Routes of administration	Intramuscular use

**Dosage and administration details:**

Doses were administered intramuscularly in the deltoid of the arm at Months 0 and 1

<b>Arm title</b>	TB Naive GSK 692342 Group
------------------	---------------------------

**Arm description:**

Subjects unaffected by tuberculosis who received the GSK 692342 vaccine according to a 2-dose schedule at Months 0 and 1.

Arm type	Experimental
Investigational medicinal product name	GSK 692342
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Injection
Routes of administration	Intramuscular use

**Dosage and administration details:**

Two doses of vaccine were administered intramuscularly in the deltoid region of the arm, on a 0, 1 Months schedule

<b>Arm title</b>	TB Naive Saline Group
------------------	-----------------------

**Arm description:**

Subjects unaffected by tuberculosis who received a placebo (physiological saline) according to a 2-dose schedule at Months 0 and 1.

Arm type	Placebo
Investigational medicinal product name	Physiological Saline
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Injection
Routes of administration	Intramuscular use

**Dosage and administration details:**

Doses were administered intramuscularly in the deltoid of the arm at Months 0 and 1

<b>Number of subjects in period 1</b>	TB Treatment GSK 692342 Group	TB Treatment Saline Group	TB Treated GSK 692342 Group
Started	7	6	24
Completed	6	5	22
Not completed	1	1	2
Consent withdrawn by subject	1	1	1
Lost to follow-up	-	-	1

<b>Number of subjects in period 1</b>	TB Treated Saline Group	TB Naive GSK 692342 Group	TB Naive Saline Group
Started	25	40	40
Completed	25	40	40
Not completed	0	0	0
Consent withdrawn by subject	-	-	-
Lost to follow-up	-	-	-

## Baseline characteristics

### Reporting groups

Reporting group title	TB Treatment GSK 692342 Group
Reporting group description:	
Subjects having completed the intensive phase of treatment, i.e. 2 to 4 months post initiation of treatment, who received the GSK 692342 vaccine according to a 2-dose schedule at Months 0 and 1.	
Reporting group title	TB Treatment Saline Group
Reporting group description:	
Subjects having completed the intensive phase of treatment, i.e. 2 to 4 months post initiation of treatment who received a placebo (physiological saline) according to a 2-dose schedule at Months 0 and 1.	
Reporting group title	TB Treated GSK 692342 Group
Reporting group description:	
Subjects having successfully completed treatment for TB disease at least 1 year prior to the study, who during this study received the GSK 692342 vaccine according to a 2-dose schedule at Months 0 and 1	
Reporting group title	TB Treated Saline Group
Reporting group description:	
Subjects having successfully completed treatment for TB disease at least 1 year prior to the study, who in this study received a placebo (physiological saline) according to a 2-dose schedule at Months 0 and 1.	
Reporting group title	TB Naive GSK 692342 Group
Reporting group description:	
Subjects unaffected by tuberculosis who received the GSK 692342 vaccine according to a 2-dose schedule at Months 0 and 1.	
Reporting group title	TB Naive Saline Group
Reporting group description:	
Subjects unaffected by tuberculosis who received a placebo (physiological saline) according to a 2-dose schedule at Months 0 and 1.	

Reporting group values	TB Treatment GSK 692342 Group	TB Treatment Saline Group	TB Treated GSK 692342 Group
Number of subjects	7	6	24
Age categorical Units: Subjects			
In utero Preterm newborn infants (gestational age < 37 wks) Newborns (0-27 days) Infants and toddlers (28 days-23 months) Children (2-11 years) Adolescents (12-17 years) Adults (18-64 years) From 65-84 years 85 years and over			
Age continuous Units: years			
arithmetic mean	42.9	44.7	44.5
standard deviation	± 11.5	± 11.8	± 10.3
Gender categorical Units: Subjects			
Female	1	2	13

Male	6	4	11
------	---	---	----

Reporting group values	TB Treated Saline Group	TB Naive GSK 692342 Group	TB Naive Saline Group
Number of subjects	25	40	40
Age categorical Units: Subjects			
In utero Preterm newborn infants (gestational age < 37 wks) Newborns (0-27 days) Infants and toddlers (28 days-23 months) Children (2-11 years) Adolescents (12-17 years) Adults (18-64 years) From 65-84 years 85 years and over			
Age continuous Units: years			
arithmetic mean standard deviation	47 ± 9.8	33.8 ± 8.5	33.3 ± 9.8
Gender categorical Units: Subjects			
Female	7	16	21
Male	18	24	19

Reporting group values	Total		
Number of subjects	142		
Age categorical Units: Subjects			
In utero Preterm newborn infants (gestational age < 37 wks) Newborns (0-27 days) Infants and toddlers (28 days-23 months) Children (2-11 years) Adolescents (12-17 years) Adults (18-64 years) From 65-84 years 85 years and over	0 0 0 0 0 0 0 0		
Age continuous Units: years			
arithmetic mean standard deviation	-		
Gender categorical Units: Subjects			
Female	60		
Male	82		





## End points

### End points reporting groups

Reporting group title	TB Treatment GSK 692342 Group
Reporting group description: Subjects having completed the intensive phase of treatment, i.e. 2 to 4 months post initiation of treatment, who received the GSK 692342 vaccine according to a 2-dose schedule at Months 0 and 1.	
Reporting group title	TB Treatment Saline Group
Reporting group description: Subjects having completed the intensive phase of treatment, i.e. 2 to 4 months post initiation of treatment who received a placebo (physiological saline) according to a 2-dose schedule at Months 0 and 1.	
Reporting group title	TB Treated GSK 692342 Group
Reporting group description: Subjects having successfully completed treatment for TB disease at least 1 year prior to the study, who during this study received the GSK 692342 vaccine according to a 2-dose schedule at Months 0 and 1	
Reporting group title	TB Treated Saline Group
Reporting group description: Subjects having successfully completed treatment for TB disease at least 1 year prior to the study, who in this study received a placebo (physiological saline) according to a 2-dose schedule at Months 0 and 1.	
Reporting group title	TB Naive GSK 692342 Group
Reporting group description: Subjects unaffected by tuberculosis who received the GSK 692342 vaccine according to a 2-dose schedule at Months 0 and 1.	
Reporting group title	TB Naive Saline Group
Reporting group description: Subjects unaffected by tuberculosis who received a placebo (physiological saline) according to a 2-dose schedule at Months 0 and 1.	

### Primary: Number of subjects with solicited local symptoms

End point title	Number of subjects with solicited local symptoms <sup>[1]</sup>
End point description:	
End point type	Primary
End point timeframe: During the 7 day (Days 0-6), after each vaccine dose	

Notes:

[1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: The analysis of the primary endpoint was descriptive i.e. no statistical hypothesis test was performed.

End point values	TB Treatment GSK 692342 Group	TB Treatment Saline Group	TB Treated GSK 692342 Group	TB Treated Saline Group
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	7	6	24	25
Units: Subjects				
Pain, D1 (N=7,6,24,25,40,40)	6	1	21	2
Redness, D1 (N=7,6,24,25,40,40)	2	0	4	0
Swelling, D1 (N=7,6,24,25,40,40)	2	0	5	1
Pain, D2 (N=6,5,21,25,39,39)	5	1	19	1

Redness, D2 (N=6,5,21,25,39,39)	3	0	7	0
Swelling, D2 (N=6,5,21,25,39,39)	3	0	4	0
Pain, Across (N=7,6,24,25,40,40)	6	1	22	3
Redness, Across (N=7,6,24,25,40,40)	3	0	8	0
Swelling, Across (N=7,6,24,25,40,40)	3	0	6	1

End point values	TB Naive GSK 692342 Group	TB Naive Saline Group		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	40	40		
Units: Subjects				
Pain, D1 (N=7,6,24,25,40,40)	38	5		
Redness, D1 (N=7,6,24,25,40,40)	7	0		
Swelling, D1 (N=7,6,24,25,40,40)	4	0		
Pain, D2 (N=6,5,21,25,39,39)	36	6		
Redness, D2 (N=6,5,21,25,39,39)	6	0		
Swelling, D2 (N=6,5,21,25,39,39)	11	0		
Pain, Across (N=7,6,24,25,40,40)	39	8		
Redness, Across (N=7,6,24,25,40,40)	10	0		
Swelling, Across (N=7,6,24,25,40,40)	11	0		

## Statistical analyses

No statistical analyses for this end point

## Primary: Number of subjects with solicited general symptoms

End point title	Number of subjects with solicited general symptoms <sup>[2]</sup>
-----------------	---

End point description:

End point type	Primary
----------------	---------

End point timeframe:

During the 7 day (Days 0-6), after each vaccine dose

Notes:

[2] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: The analysis of the primary endpoint was descriptive i.e. no statistical hypothesis test was performed.

End point values	TB Treatment GSK 692342 Group	TB Treatment Saline Group	TB Treated GSK 692342 Group	TB Treated Saline Group
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	7	6	24	25
Units: Subjects				
Fatigue, D1 (N=7,6,24,25,40,40)	1	2	14	6
Gastrointestinal symptoms, D1 (N=7,6,24,25,40,40)	0	0	4	2
Headache, D1 (N=7,6,24,25,40,40)	1	0	11	4
Malaise, D1 (N=7,6,24,25,40,40)	1	1	11	2

Myalgia, D1 (N=7,6,24,25,40,40)	2	0	13	4
Temperature/(Axillary), D1 (N=7,6,24,25,40,40)	0	0	1	0
Fatigue, D2 (N=6,5,21,25,39,39)	3	1	13	5
Gastrointestinal symptoms, D2 (N=6,5,21,25,39,39)	2	0	7	3
Headache, D2 (N=6,5,21,25,39,39)	3	1	12	2
Malaise, D2 (N=6,5,21,25,39,39)	3	2	11	5
Myalgia, D2 (N=6,5,21,25,39,39)	3	1	14	4
Temperature/(Axillary), D2 (N=6,5,21,25,39,39)	4	1	9	0
Fatigue, Across (N=7,6,24,25,40,40)	3	2	17	8
Gastrointestinal symptoms, Across (N=7,6,24,25,40,40)	2	0	10	4
Headache, Across (N=7,6,24,25,40,40)	3	1	18	4
Malaise, Across (N=7,6,24,25,40,40)	3	2	16	6
Myalgia, Across (N=7,6,24,25,40,40)	3	1	18	5
Temperature/(Axillary), Across (N=7,6,24,25,40,40)	4	1	10	0

<b>End point values</b>	TB Naive GSK 692342 Group	TB Naive Saline Group		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	40	40		
Units: Subjects				
Fatigue, D1 (N=7,6,24,25,40,40)	19	8		
Gastrointestinal symptoms, D1 (N=7,6,24,25,40,40)	5	5		
Headache, D1 (N=7,6,24,25,40,40)	8	5		
Malaise, D1 (N=7,6,24,25,40,40)	14	8		
Myalgia, D1 (N=7,6,24,25,40,40)	24	7		
Temperature/(Axillary), D1 (N=7,6,24,25,40,40)	2	0		
Fatigue, D2 (N=6,5,21,25,39,39)	33	7		
Gastrointestinal symptoms, D2 (N=6,5,21,25,39,39)	13	3		
Headache, D2 (N=6,5,21,25,39,39)	22	3		
Malaise, D2 (N=6,5,21,25,39,39)	32	3		
Myalgia, D2 (N=6,5,21,25,39,39)	28	3		
Temperature/(Axillary), D2 (N=6,5,21,25,39,39)	16	0		
Fatigue, Across (N=7,6,24,25,40,40)	36	10		
Gastrointestinal symptoms, Across (N=7,6,24,25,40,40)	16	6		
Headache, Across (N=7,6,24,25,40,40)	24	6		
Malaise, Across (N=7,6,24,25,40,40)	35	9		
Myalgia, Across (N=7,6,24,25,40,40)	34	7		
Temperature/(Axillary), Across (N=7,6,24,25,40,40)	17	0		

## Statistical analyses

No statistical analyses for this end point

### Primary: Number of subjects with adverse events (AEs)

End point title	Number of subjects with adverse events (AEs) <sup>[3]</sup>
-----------------	---

End point description:

End point type	Primary
----------------	---------

End point timeframe:

During the 30 day (Days 0-29) after vaccination

Notes:

[3] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: The analysis of the primary endpoint was descriptive i.e. no statistical hypothesis test was performed.

End point values	TB Treatment GSK 692342 Group	TB Treatment Saline Group	TB Treated GSK 692342 Group	TB Treated Saline Group
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	7	6	24	25
Units: Subjects				
Any AEs	1	2	14	7

End point values	TB Naive GSK 692342 Group	TB Naive Saline Group		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	40	40		
Units: Subjects				
Any AEs	19	8		

## Statistical analyses

No statistical analyses for this end point

### Primary: Number of subjects with serious adverse events (SAEs)

End point title	Number of subjects with serious adverse events (SAEs) <sup>[4]</sup>
-----------------	--

End point description:

End point type	Primary
----------------	---------

End point timeframe:

Up to day 210

Notes:

[4] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: The analysis of the primary endpoint was descriptive i.e. no statistical hypothesis test was performed.

End point values	TB Treatment GSK 692342 Group	TB Treatment Saline Group	TB Treated GSK 692342 Group	TB Treated Saline Group
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	7	6	24	25
Units: Subjects				
Any SAEs	0	0	2	2

End point values	TB Naive GSK 692342 Group	TB Naive Saline Group		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	40	40		
Units: Subjects				
Any SAEs	1	0		

### Statistical analyses

No statistical analyses for this end point

### Secondary: Number of subjects with anti-mycobacterium tuberculosis fusion protein M72 antibodies.

End point title	Number of subjects with anti-mycobacterium tuberculosis fusion protein M72 antibodies.
-----------------	--

End point description:

Cut-off values assessed were greater than or equal to 2.8 measured by ELISA (Enzyme Linked Immunosorbent Assay) in the sera of subjects seronegative before vaccination.

End point type	Secondary
----------------	-----------

End point timeframe:

Prior to dose 1 (Day 0 - PRE), post-dose 1 (Day 30 - D30), post-dose 2 (Days 60 - D60 and 210 - D210)

End point values	TB Treatment GSK 692342 Group	TB Treatment Saline Group	TB Treated GSK 692342 Group	TB Treated Saline Group
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	7	4	21	25
Units: Subjects				
Anti-M72, PRE (N=7; 4; 21; 25; 37; 39)	0	0	0	0
Anti-M72, D30 (N=6; 4; 21; 25; 38; 39)	5	0	19	0
Anti-M72, D60 (N=6; 3; 19; 25; 38; 39)	6	0	18	0
Anti-M72, D210 (N=6; 3; 19; 25; 38; 39)	6	0	18	0

End point values	TB Naive GSK	TB Naive Saline		
------------------	--------------	-----------------	--	--

	692342 Group	Group		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	38	39		
Units: Subjects				
Anti-M72, PRE (N=7; 4; 21; 25; 37; 39)	1	2		
Anti-M72, D30 (N=6; 4; 21; 25; 38; 39)	26	2		
Anti-M72, D60 (N=6; 3; 19; 25; 38; 39)	37	3		
Anti-M72, D210 (N=6; 3; 19; 25; 38; 39)	38	1		

## Statistical analyses

No statistical analyses for this end point

## Secondary: Concentrations of mycobacterium tuberculosis fusion protein M72.

End point title	Concentrations of mycobacterium tuberculosis fusion protein M72.
End point description:	
Concentrations are presented as geometric mean concentrations (GMCs), expressed in ELISA units per millilitre (EU/mL)	
End point type	Secondary
End point timeframe:	
Prior to dose 1 (Day 0 - PRE), post-dose 1 (Day 30 - D30), post-dose 2 (Days 60 - D60 and 210 - D210)	

End point values	TB Treatment GSK 692342 Group	TB Treatment Saline Group	TB Treated GSK 692342 Group	TB Treated Saline Group
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	7	4	21	25
Units: EU/mL				
geometric mean (confidence interval 95%)				
Anti-M72, PRE (N=7; 4; 21; 25; 37; 39)	1.4 (1.4 to 1.4)	1.4 (1.4 to 1.4)	1.4 (1.4 to 1.4)	1.4 (1.4 to 1.4)
Anti-M72, D30 (N=6; 4; 21; 25; 38; 39)	6.7 (2.1 to 21)	1.4 (1.4 to 1.4)	11.7 (6.3 to 22)	1.4 (1.4 to 1.4)
Anti-M72, D60 (N=6; 3; 19; 25; 38; 39)	206.6 (46.2 to 923.2)	1.4 (1.4 to 1.4)	226.2 (99 to 517.2)	1.4 (1.4 to 1.4)
Anti-M72, D210 (N=6; 3; 19; 25; 38; 39)	38.4 (18.9 to 77.9)	1.4 (1.4 to 1.4)	50.9 (27.3 to 94.8)	1.4 (1.4 to 1.4)

End point values	TB Naive GSK 692342 Group	TB Naive Saline Group		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	38	39		
Units: EU/mL				
geometric mean (confidence interval				

95%)				
Anti-M72, PRE (N=7; 4; 21; 25; 37; 39)	1.4 (1.4 to 1.5)	1.5 (1.4 to 1.6)		
Anti-M72, D30 (N=6; 4; 21; 25; 38; 39)	4.5 (3.3 to 6.2)	1.5 (1.4 to 1.6)		
Anti-M72, D60 (N=6; 3; 19; 25; 38; 39)	248.6 (171 to 361.4)	1.7 (1.3 to 2.3)		
Anti-M72, D210 (N=6; 3; 19; 25; 38; 39)	45.6 (34.2 to 60.8)	1.4 (1.4 to 1.5)		

## Statistical analyses

No statistical analyses for this end point

## Secondary: Frequency of M72-specific CD4+ T cells per million cells expressing any combination of the different immune markers.

End point title	Frequency of M72-specific CD4+ T cells per million cells expressing any combination of the different immune markers.
-----------------	--

End point description:

Immune markers expressed were among Interleukin-2 (IL-2), Interferon-gamma (IFN-g), Tumour necrosis factor-alpha (TNF-a) and/or CD40-ligand (CD40-L).

End point type	Secondary
----------------	-----------

End point timeframe:

Prior to dose 1 (Day 0 - PRE), post-dose 1 (Days 7 - D7 and 30 - D30), post-dose 2 (Days 37 - D37, 60 - D60 and 210 - D210)

End point values	TB Treatment GSK 692342 Group	TB Treatment Saline Group	TB Treated GSK 692342 Group	TB Treated Saline Group
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	6	3	18	22
Units: T cells/million cells				
median (inter-quartile range (Q1-Q3))				
CD4-ALL doubles, PRE (N=4; 3; 15; 22; 30; 30)	247 (204.5 to 333.5)	178 (70 to 651)	347 (196 to 523)	549.5 (375 to 997)
CD4-ALL doubles, D7 (N=4; 3; 13; 15; 26; 28)	997.5 (714 to 1345)	182 (82 to 431)	1097 (985 to 1760)	469 (328 to 1075)
CD4-ALL doubles, D30 (N=5; 2; 16; 16; 34; 34)	2959 (1289 to 2989)	730 (216 to 1244)	2616.5 (1417 to 5614)	466 (261.5 to 1145.5)
CD4-ALL doubles, D37 (N=5; 3; 18; 19; 34; 34)	4433 (3024 to 10010)	273 (221 to 445)	5705.5 (2219 to 11228)	533 (227 to 1235)
CD4-ALL doubles, D60 (N=4; 2; 15; 18; 31; 32)	5648 (3686 to 7957)	241 (224 to 258)	2072 (1083 to 4199)	517 (352 to 1242)
CD4-ALL doubles, D210 (N=6; 3; 13; 17; 37; 36)	2922.5 (967 to 4411)	118 (116 to 307)	1154 (1028 to 1808)	445 (243 to 734)

End point values	TB Naive GSK 692342 Group	TB Naive Saline Group		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	37	36		

Units: T cells/million cells				
median (inter-quartile range (Q1-Q3))				
CD4-ALL doubles, PRE (N=4; 3; 15; 22; 30; 30)	286 (173 to 471)	352 (170 to 579)		
CD4-ALL doubles, D7 (N=4; 3; 13; 15; 26; 28)	801.5 (440 to 1492)	265.5 (167.5 to 571.5)		
CD4-ALL doubles, D30 (N=5; 2; 16; 16; 34; 34)	1228.5 (941 to 2131)	312.5 (202 to 726)		
CD4-ALL doubles, D37 (N=5; 3; 18; 19; 34; 34)	5987.5 (3987 to 9605)	247 (175 to 387)		
CD4-ALL doubles, D60 (N=4; 2; 15; 18; 31; 32)	5153 (2884 to 8978)	240 (146 to 476)		
CD4-ALL doubles, D210 (N=6; 3; 13; 17; 37; 36)	2155 (1389 to 4160)	254 (166 to 383)		

## Statistical analyses

No statistical analyses for this end point

### Secondary: Frequency of M72-specific CD4+ T cells per million cells expressing 2 or more immune markers among 6.

End point title	Frequency of M72-specific CD4+ T cells per million cells expressing 2 or more immune markers among 6.
-----------------	---

End point description:

Immune markers expressed were among Interleukin-2 (IL-2), Interferon-gamma (IFN-g), Tumour necrosis factor-alpha (TNF-a), CD40-ligand (CD40-L), Interleukin-17 (IL-17) and/or Interleukin-17 (IL-17).

End point type	Secondary
----------------	-----------

End point timeframe:

Prior to dose 1 (Day 0 - PRE), post-dose 1 (Days 7 - D7 and 30 - D30), post-dose 2 (Days 37 - D37, 60 - D60 and 210 - D210)

End point values	TB Treatment GSK 692342 Group	TB Treatment Saline Group	TB Treated GSK 692342 Group	TB Treated Saline Group
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	6	3	16	22
Units: T cells/million cells				
median (inter-quartile range (Q1-Q3))				
CD4-At least 2, PRE (N=4; 3; 15; 22; 30; 30)	260 (217.5 to 346.5)	207 (96 to 687)	364 (238 to 536)	562.5 (402 to 1010)
CD4- At least 2, D7 (N=4; 3; 13; 15; 26; 28)	1010.5 (733.5 to 1358)	208 (95 to 457)	1152 (1011 to 1895)	482 (347 to 1088)
CD4- At least 2, D30 (N=5; 2; 16; 16; 34; 34)	2972 (1302 to 3002)	765 (229 to 1301)	2636 (1437 to 5655)	497 (282 to 1179)
CD4- At least 2, D37 (N=5; 3; 18; 19; 34; 34)	4446 (3037 to 10107)	316 (234 to 458)	5733.5 (2232 to 11281)	565 (260 to 1262)
CD4- At least 2, D60 (N=4; 2; 15; 18; 31; 32)	5661 (3699 to 7976.5)	254 (237 to 271)	2101 (1115 to 4275)	583 (378 to 1256)
CD4- At least 2, D210 (N=6; 3; 13; 17; 37; 36)	2948.5 (993 to 4670)	131 (129 to 320)	1167 (1041 to 1821)	480 (298 to 770)



End point values	TB Naive GSK 692342 Group	TB Naive Saline Group		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	37	36		
Units: T cells/million cells				
median (inter-quartile range (Q1-Q3))				
CD4-At least 2, PRE (N=4; 3; 15; 22; 30; 30)	325 (240 to 512)	365 (214 to 609)		
CD4- At least 2, D7 (N=4; 3; 13; 15; 26; 28)	856 (479 to 1505)	278.5 (193.5 to 600)		
CD4- At least 2, D30 (N=5; 2; 16; 16; 34; 34)	1248.5 (954 to 2144)	348.5 (238 to 754)		
CD4- At least 2, D37 (N=5; 3; 18; 19; 34; 34)	6051.5 (4191 to 9679)	277.5 (190 to 425)		
CD4- At least 2, D60 (N=4; 2; 15; 18; 31; 32)	5185 (2897 to 9031)	258 (160.5 to 496)		
CD4- At least 2, D210 (N=6; 3; 13; 17; 37; 36)	2269 (1419 to 4173)	299 (201.5 to 449.5)		

## Statistical analyses

No statistical analyses for this end point

## Secondary: Frequency of M72-specific CD4+ T cells per million cells expressing any combination of immune markers.

End point title	Frequency of M72-specific CD4+ T cells per million cells expressing any combination of immune markers.
End point description:	Immune markers expressed were among Interleukin-2 (IL-2), Interferon-gamma (IFN-g), Tumour necrosis factor-alpha (TNF-a) and/or CD40-ligand (CD40-L).
End point type	Secondary
End point timeframe:	Prior to dose 1 (Day 0 - PRE), post-dose 1 (Days 7 - D7 and 30 - D30), post-dose 2 (Days 37 - D37, 60 - D60 and 210 - D210)

End point values	TB Treatment GSK 692342 Group	TB Treatment Saline Group	TB Treated GSK 692342 Group	TB Treated Saline Group
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	6	3	18	22
Units: T cells/million cells				
median (inter-quartile range (Q1-Q3))				
CD40L+/IL2+/TNFa+/IFNg+, PRE (N=4;3;15;22;30;30)	106.5 (68 to 134)	4 (4 to 252)	87 (34 to 140)	124 (74 to 186)
CD40L+/IL2+/TNFa+/IFNg+, D7 (N=4;3;13;15;26;28)	267.5 (218.5 to 493.5)	42 (4 to 241)	329 (140 to 454)	84 (25 to 154)
CD40L+/IL2+/TNFa+/IFNg+, D30 (N=5;2;16;16;34;34)	1066 (261 to 1233)	330.5 (33 to 628)	776 (341 to 1070.5)	71 (30.5 to 161.5)

CD40L+/IL2+/TNFa+/IFNg+, D37 (N=5;3;18;19;34;34)	1186 (1084 to 1403)	80 (44 to 158)	897.5 (333 to 1123)	87 (52 to 135)
CD40L+/IL2+/TNFa+/IFNg+, D60 (N=4;2;15;18;31;32)	1444 (1039 to 1615.5)	4 (4 to 4)	417 (87 to 815)	132 (73 to 171)
CD40L+/IL2+/TNFa+/IFNg+, D210 (N=6;3;13;17;37;36)	585.5 (288 to 997)	18 (4 to 74)	288 (217 to 313)	68 (38 to 157)
CD40L+/IL2+/TNFa+/IFNg-, PRE (N=4;3;15;22;30;30)	12 (4 to 22)	55 (4 to 93)	25 (4 to 48)	20.5 (4 to 58)
CD40L+/IL2+/TNFa+/IFNg-, D7 (N=4;3;13;15;26;28)	33 (17 to 44)	17 (4 to 45)	44 (31 to 116)	27 (4 to 34)
CD40L+/IL2+/TNFa+/IFNg-, D30 (N=5;2;16;16;34;34)	204 (162 to 213)	48 (4 to 92)	250 (149.5 to 370.5)	16 (4 to 43)
CD40L+/IL2+/TNFa+/IFNg-, D37 (N=5;3;18;19;34;34)	436 (246 to 550)	35 (31 to 49)	292 (154 to 525)	9 (4 to 43)
CD40L+/IL2+/TNFa+/IFNg-, D60 (N=4;2;15;18;31;32)	654 (561.5 to 1140.5)	28 (24 to 32)	301 (183 to 458)	19 (4 to 42)
CD40L+/IL2+/TNFa+/IFNg-, D210 (N=6;3;13;17;37;36)	448 (202 to 552)	4 (4 to 5)	148 (116 to 209)	18 (4 to 31)

End point values	TB Naive GSK 692342 Group	TB Naive Saline Group		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	37	36		
Units: T cells/million cells				
median (inter-quartile range (Q1-Q3))				
CD40L+/IL2+/TNFa+/IFNg+, PRE (N=4;3;15;22;30;30)	60 (4 to 108)	54 (17 to 142)		
CD40L+/IL2+/TNFa+/IFNg+, D7 (N=4;3;13;15;26;28)	87 (24 to 229)	55.5 (4 to 132)		
CD40L+/IL2+/TNFa+/IFNg+, D30 (N=5;2;16;16;34;34)	89.5 (37 to 287)	47 (17 to 157)		
CD40L+/IL2+/TNFa+/IFNg+, D37 (N=5;3;18;19;34;34)	436.5 (192 to 592)	45 (11 to 106)		
CD40L+/IL2+/TNFa+/IFNg+, D60 (N=4;2;15;18;31;32)	436 (219 to 826)	31 (4 to 130.5)		
CD40L+/IL2+/TNFa+/IFNg+, D210 (N=6;3;13;17;37;36)	201 (95 to 504)	35.5 (18 to 89.5)		
CD40L+/IL2+/TNFa+/IFNg-, PRE (N=4;3;15;22;30;30)	4 (4 to 26)	4 (4 to 33)		
CD40L+/IL2+/TNFa+/IFNg-, D7 (N=4;3;13;15;26;28)	19 (4 to 54)	16.5 (4 to 34)		
CD40L+/IL2+/TNFa+/IFNg-, D30 (N=5;2;16;16;34;34)	279.5 (144 to 385)	20.5 (4 to 50)		
CD40L+/IL2+/TNFa+/IFNg-, D37 (N=5;3;18;19;34;34)	558.5 (250 to 884)	4.5 (4 to 37)		
CD40L+/IL2+/TNFa+/IFNg-, D60 (N=4;2;15;18;31;32)	1117 (551 to 1690)	20 (4 to 33)		
CD40L+/IL2+/TNFa+/IFNg-, D210 (N=6;3;13;17;37;36)	566 (245 to 997)	4 (4 to 27.5)		

## Statistical analyses

No statistical analyses for this end point

## Secondary: Frequency of M72-specific CD4+ T cells per million cells expressing any combination of immune markers.

End point title	Frequency of M72-specific CD4+ T cells per million cells expressing any combination of immune markers.
End point description: Immune markers expressed were among Interleukin-2 (IL-2), Interferon-gamma (IFN-g), Tumour necrosis factor-alpha (TNF-a) and/or CD40-ligand (CD40-L).	
End point type	Secondary
End point timeframe: Prior to dose 1 (Day 0 - PRE), post-dose 1 (Days 7 - D7 and 30 - D30), post-dose 2 (Days 37 - D37, 60 - D60 and 210 - D210)	

End point values	TB Treatment GSK 692342 Group	TB Treatment Saline Group	TB Treated GSK 692342 Group	TB Treated Saline Group
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	6	3	18	22
Units: T cells/million cells				
median (inter-quartile range (Q1-Q3))				
CD40L+/IL2+/TNFa-/IFNg+, PRE (N=4;3;15;22;30;30)	4 (4 to 11)	4 (4 to 26)	4 (4 to 23)	17 (4 to 31)
CD40L+/IL2+/TNFa-/IFNg+, D7 (N=4;3;13;15;26;28)	33 (12 to 50.5)	4 (4 to 47)	40 (31 to 103)	4 (4 to 19)
CD40L+/IL2+/TNFa-/IFNg+, D30 (N=5;2;16;16;34;34)	48 (47 to 117)	25.5 (4 to 47)	82.5 (39 to 116)	4 (4 to 18.5)
CD40L+/IL2+/TNFa-/IFNg+, D37 (N=5;3;18;19;34;34)	118 (89 to 307)	4 (4 to 19)	133.5 (42 to 242)	4 (4 to 20)
CD40L+/IL2+/TNFa-/IFNg+, D60 (N=4;2;15;18;31;32)	151.5 (129.5 to 246)	32 (4 to 60)	75 (44 to 236)	4 (4 to 18)
CD40L+/IL2+/TNFa-/IFNg+, D210 (N=6;3;13;17;37;36)	112.5 (31 to 218)	18 (4 to 60)	47 (24 to 95)	4 (4 to 29)
CD40L+/IL2+/TNFa-/IFNg-, PRE (N=4;3;15;22;30;30)	11.5 (4 to 41)	4 (4 to 17)	14 (4 to 22)	17.5 (4 to 45)
CD40L+/IL2+/TNFa-/IFNg-, D7 (N=4;3;13;15;26;28)	45.5 (4 to 88)	4 (4 to 17)	43 (17 to 75)	4 (4 to 46)
CD40L+/IL2+/TNFa-/IFNg-, D30 (N=5;2;16;16;34;34)	102 (32 to 201)	84.5 (33 to 136)	150.5 (69 to 253.5)	25 (4 to 53)
CD40L+/IL2+/TNFa-/IFNg-, D37 (N=5;3;18;19;34;34)	263 (94 to 305)	20 (4 to 65)	182 (67 to 393)	4 (4 to 29)
CD40L+/IL2+/TNFa-/IFNg-, D60 (N=4;2;15;18;31;32)	381.5 (223.5 to 561.5)	46.5 (32 to 61)	171 (84 to 514)	4 (4 to 38)
CD40L+/IL2+/TNFa-/IFNg-, D210 (N=6;3;13;17;37;36)	166.5 (66 to 380)	18 (4 to 31)	126 (101 to 148)	17 (4 to 32)

End point values	TB Naive GSK 692342 Group	TB Naive Saline Group		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	37	36		
Units: T cells/million cells				
median (inter-quartile range (Q1-Q3))				
CD40L+/IL2+/TNFa-/IFNg+, PRE (N=4;3;15;22;30;30)	4 (4 to 27)	12.5 (4 to 34)		

CD40L+/IL2+/TNFa-/IFNg+, D7 (N=4;3;13;15;26;28)	32.5 (4 to 84)	4 (4 to 27.5)		
CD40L+/IL2+/TNFa-/IFNg+, D30 (N=5;2;16;16;34;34)	39.5 (25 to 76)	17 (4 to 37)		
CD40L+/IL2+/TNFa-/IFNg+, D37 (N=5;3;18;19;34;34)	278 (161 to 525)	17 (4 to 47)		
CD40L+/IL2+/TNFa-/IFNg+, D60 (N=4;2;15;18;31;32)	269 (128 to 500)	4 (4 to 28.5)		
CD40L+/IL2+/TNFa-/IFNg+, D210 (N=6;3;13;17;37;36)	126 (61 to 296)	10.5 (4 to 40)		
CD40L+/IL2+/TNFa-/IFNg-, PRE (N=4;3;15;22;30;30)	19.5 (4 to 37)	4 (4 to 24)		
CD40L+/IL2+/TNFa-/IFNg-, D7 (N=4;3;13;15;26;28)	44.5 (4 to 69)	5 (4 to 49.5)		
CD40L+/IL2+/TNFa-/IFNg-, D30 (N=5;2;16;16;34;34)	300 (202 to 519)	18 (4 to 49)		
CD40L+/IL2+/TNFa-/IFNg-, D37 (N=5;3;18;19;34;34)	732 (498 to 946)	4 (4 to 16)		
CD40L+/IL2+/TNFa-/IFNg-, D60 (N=4;2;15;18;31;32)	939 (534 to 1537)	17.5 (4 to 30)		
CD40L+/IL2+/TNFa-/IFNg-, D210 (N=6;3;13;17;37;36)	453 (281 to 768)	11 (4 to 37)		

## Statistical analyses

No statistical analyses for this end point

## Secondary: Frequency of M72-specific CD4+ T cells per million cells expressing any combination of immune markers.

End point title	Frequency of M72-specific CD4+ T cells per million cells expressing any combination of immune markers.
-----------------	--

End point description:

Immune markers expressed were among Interleukin-2 (IL-2), Interferon-gamma (IFN-g), Tumour necrosis factor-alpha (TNF-a) and/or CD40-ligand (CD40-L).

End point type	Secondary
----------------	-----------

End point timeframe:

Prior to dose 1 (Day 0 - PRE), post-dose 1 (Days 7 - D7 and 30 - D30), post-dose 2 (Days 37 - D37, 60 - D60 and 210 - D210)

End point values	TB Treatment GSK 692342 Group	TB Treatment Saline Group	TB Treated GSK 692342 Group	TB Treated Saline Group
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	6	3	18	22
Units: T cells/million cells				
median (inter-quartile range (Q1-Q3))				
CD40L+/IL2-/TNFa+/IFNg+, PRE (N=4;3;15;22;30;30)	67 (47 to 74.5)	55 (4 to 161)	61 (19 to 218)	188.5 (66 to 272)
CD40L+/IL2-/TNFa+/IFNg+, D7 (N=4;3;13;15;26;28)	270.5 (224 to 408.5)	4 (4 to 73)	389 (207 to 735)	151 (79 to 278)
CD40L+/IL2-/TNFa+/IFNg+, D30 (N=5;2;16;16;34;34)	563 (541 to 1023)	115 (4 to 226)	902 (397.5 to 2177)	132.5 (54.5 to 398)

CD40L+/IL2-/TNFa+/IFNg+, D37 (N=5;3;18;19;34;34)	1236 (886 to 3361)	4 (4 to 111)	1828 (462 to 3273)	253 (45 to 463)
CD40L+/IL2-/TNFa+/IFNg+, D60 (N=4;2;15;18;31;32)	2219.5 (1183 to 3234)	24.5 (4 to 45)	608 (361 to 1433)	149.5 (97 to 340)
CD40L+/IL2-/TNFa+/IFNg+, D210 (N=6;3;13;17;37;36)	869 (202 to 1422)	32 (4 to 33)	439 (218 to 620)	174 (46 to 248)
CD40L+/IL2-/TNFa+/IFNg-, PRE (N=4;3;15;22;30;30)	10 (4 to 20.5)	20 (4 to 73)	8 (4 to 38)	18 (4 to 43)
CD40L+/IL2-/TNFa+/IFNg-, D7 (N=4;3;13;15;26;28)	34 (18 to 40.5)	17 (4 to 47)	58 (24 to 74)	4 (4 to 31)
CD40L+/IL2-/TNFa+/IFNg-, D30 (N=5;2;16;16;34;34)	132 (45 to 150)	25.5 (4 to 47)	152.5 (79 to 215)	25.5 (4 to 52.5)
CD40L+/IL2-/TNFa+/IFNg-, D37 (N=5;3;18;19;34;34)	276 (117 to 889)	37 (4 to 87)	375.5 (230 to 805)	40 (4 to 84)
CD40L+/IL2-/TNFa+/IFNg-, D60 (N=4;2;15;18;31;32)	359.5 (255 to 556.5)	62.5 (4 to 121)	176 (75 to 327)	26 (4 to 65)
CD40L+/IL2-/TNFa+/IFNg-, D210 (N=6;3;13;17;37;36)	167 (75 to 191)	19 (4 to 35)	77 (23 to 134)	4 (4 to 40)

End point values	TB Naive GSK 692342 Group	TB Naive Saline Group		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	37	36		
Units: T cells/million cells				
median (inter-quartile range (Q1-Q3))				
CD40L+/IL2-/TNFa+/IFNg+, PRE (N=4;3;15;22;30;30)	48.5 (17 to 101)	44.5 (19 to 164)		
CD40L+/IL2-/TNFa+/IFNg+, D7 (N=4;3;13;15;26;28)	232 (46 to 491)	43 (10.5 to 148.5)		
CD40L+/IL2-/TNFa+/IFNg+, D30 (N=5;2;16;16;34;34)	156.5 (76 to 481)	71.5 (18 to 221)		
CD40L+/IL2-/TNFa+/IFNg+, D37 (N=5;3;18;19;34;34)	738.5 (422 to 1663)	46.5 (17 to 114)		
CD40L+/IL2-/TNFa+/IFNg+, D60 (N=4;2;15;18;31;32)	560 (192 to 1563)	55.5 (25.5 to 150)		
CD40L+/IL2-/TNFa+/IFNg+, D210 (N=6;3;13;17;37;36)	301 (137 to 602)	22 (4 to 137)		
CD40L+/IL2-/TNFa+/IFNg-, PRE (N=4;3;15;22;30;30)	9.5 (4 to 47)	20 (4 to 52)		
CD40L+/IL2-/TNFa+/IFNg-, D7 (N=4;3;13;15;26;28)	40.5 (17 to 98)	4 (4 to 41)		
CD40L+/IL2-/TNFa+/IFNg-, D30 (N=5;2;16;16;34;34)	125.5 (71 to 216)	17 (4 to 28)		
CD40L+/IL2-/TNFa+/IFNg-, D37 (N=5;3;18;19;34;34)	915 (471 to 1575)	18 (4 to 38)		
CD40L+/IL2-/TNFa+/IFNg-, D60 (N=4;2;15;18;31;32)	792 (421 to 1060)	4 (4 to 38.5)		
CD40L+/IL2-/TNFa+/IFNg-, D210 (N=6;3;13;17;37;36)	272 (142 to 358)	18 (4 to 34.5)		

## Statistical analyses

No statistical analyses for this end point

**Secondary: Frequency of M72-specific CD4+ T cells per million cells expressing any combination of immune markers.**

End point title	Frequency of M72-specific CD4+ T cells per million cells expressing any combination of immune markers.
End point description: Immune markers expressed were among Interleukin-2 (IL-2), Interferon-gamma (IFN-g), Tumour necrosis factor-alpha (TNF-a) and/or CD40-ligand (CD40-L).	
End point type	Secondary
End point timeframe: Prior to dose 1 (Day 0 - PRE), post-dose 1 (Days 7 - D7 and 30 - D30), post-dose 2 (Days 37 - D37, 60 - D60 and 210 - D210)	

End point values	TB Treatment GSK 692342 Group	TB Treatment Saline Group	TB Treated GSK 692342 Group	TB Treated Saline Group
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	6	3	18	22
Units: T cells/million cells				
median (inter-quartile range (Q1-Q3))				
CD40L+/IL2-/TNFa-/IFNg+, PRE (N=4;3;15;22;30;30)	10.5 (4 to 40)	17 (4 to 20)	25 (6 to 61)	43 (4 to 80)
CD40L+/IL2-/TNFa-/IFNg+, D7 (N=4;3;13;15;26;28)	113.5 (62.5 to 155.5)	4 (4 to 31)	227 (65 to 469)	22 (4 to 71)
CD40L+/IL2-/TNFa-/IFNg+, D30 (N=5;2;16;16;34;34)	71 (60 to 75)	41 (32 to 50)	124.5 (64.5 to 284)	13.5 (4 to 65)
CD40L+/IL2-/TNFa-/IFNg+, D37 (N=5;3;18;19;34;34)	406 (406 to 1923)	5 (4 to 31)	649 (245 to 1982)	17 (4 to 72)
CD40L+/IL2-/TNFa-/IFNg+, D60 (N=4;2;15;18;31;32)	213 (75 to 378.5)	17.5 (4 to 31)	147 (58 to 339)	20.5 (4 to 46)
CD40L+/IL2-/TNFa-/IFNg+, D210 (N=6;3;13;17;37;36)	129 (18 to 304)	4 (4 to 73)	57 (37 to 115)	32 (4 to 62)
CD40L+/IL2-/TNFa-/IFNg-, PRE (N=4;3;15;22;30;30)	4 (4 to 98.5)	103 (4 to 244)	19 (4 to 41)	10.5 (4 to 73)
CD40L+/IL2-/TNFa-/IFNg-, D7 (N=4;3;13;15;26;28)	4 (4 to 10.5)	4 (4 to 506)	14 (4 to 83)	4 (4 to 23)
CD40L+/IL2-/TNFa-/IFNg-, D30 (N=5;2;16;16;34;34)	4 (4 to 18)	1375.5 (4 to 2747)	208 (11 to 689)	4 (4 to 37)
CD40L+/IL2-/TNFa-/IFNg-, D37 (N=5;3;18;19;34;34)	973 (17 to 1644)	213 (20 to 373)	1544 (787 to 2630)	18 (4 to 200)
CD40L+/IL2-/TNFa-/IFNg-, D60 (N=4;2;15;18;31;32)	4 (4 to 373.5)	4 (4 to 4)	168 (4 to 727)	4 (4 to 104)
CD40L+/IL2-/TNFa-/IFNg-, D210 (N=6;3;13;17;37;36)	10.5 (4 to 712)	4 (4 to 4)	296 (13 to 743)	45 (4 to 233)

End point values	TB Naive GSK 692342 Group	TB Naive Saline Group		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	37	36		
Units: T cells/million cells				
median (inter-quartile range (Q1-Q3))				
CD40L+/IL2-/TNFa-/IFNg+, PRE (N=4;3;15;22;30;30)	27.5 (4 to 54)	12 (4 to 60)		

CD40L+/IL2-/TNFa-/IFNg+, D7 (N=4;3;13;15;26;28)	163 (100 to 239)	29.5 (4 to 54)		
CD40L+/IL2-/TNFa-/IFNg+, D30 (N=5;2;16;16;34;34)	86.5 (27 to 154)	30 (4 to 59)		
CD40L+/IL2-/TNFa-/IFNg+, D37 (N=5;3;18;19;34;34)	1355.5 (917 to 2882)	19 (4 to 58)		
CD40L+/IL2-/TNFa-/IFNg+, D60 (N=4;2;15;18;31;32)	399 (135 to 664)	4 (4 to 35.5)		
CD40L+/IL2-/TNFa-/IFNg+, D210 (N=6;3;13;17;37;36)	107 (65 to 180)	30.5 (5 to 48)		
CD40L+/IL2-/TNFa-/IFNg-, PRE (N=4;3;15;22;30;30)	4 (4 to 29)	4 (4 to 32)		
CD40L+/IL2-/TNFa-/IFNg-, D7 (N=4;3;13;15;26;28)	19 (4 to 171)	4 (4 to 41.5)		
CD40L+/IL2-/TNFa-/IFNg-, D30 (N=5;2;16;16;34;34)	342 (133 to 769)	4 (4 to 136)		
CD40L+/IL2-/TNFa-/IFNg-, D37 (N=5;3;18;19;34;34)	3575.5 (2450 to 6212)	4 (4 to 32)		
CD40L+/IL2-/TNFa-/IFNg-, D60 (N=4;2;15;18;31;32)	1426 (653 to 2820)	4 (4 to 89)		
CD40L+/IL2-/TNFa-/IFNg-, D210 (N=6;3;13;17;37;36)	497 (34 to 900)	4 (4 to 89.5)		

### Statistical analyses

No statistical analyses for this end point

### Secondary: Frequency of M72-specific CD4+ T cells per million cells expressing any combination of immune markers.

End point title	Frequency of M72-specific CD4+ T cells per million cells expressing any combination of immune markers.
End point description: Immune markers expressed were among Interleukin-2 (IL-2), Interferon-gamma (IFN-g), Tumour necrosis factor-alpha (TNF-a) and/or CD40-ligand (CD40-L).	
End point type	Secondary
End point timeframe: Prior to dose 1 (Day 0 - PRE), post-dose 1 (Days 7 – D7 and 30 – D30), post-dose 2 (Days 37 – D37, 60 – D60 and 210 – D210)	

End point values	TB Treatment GSK 692342 Group	TB Treatment Saline Group	TB Treated GSK 692342 Group	TB Treated Saline Group
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	6	3	18	22
Units: T cells/million cells				
median (inter-quartile range (Q1-Q3))				
CD40L-/IL2+/TNFa+/IFNg+, PRE (N=4;3;15;22;30;30)	4 (4 to 4)	4 (4 to 26)	4 (4 to 4)	4 (4 to 4)
CD40L-/IL2+/TNFa+/IFNg+, D7 (N=4;3;13;15;26;28)	4 (4 to 68)	4 (4 to 17)	19 (4 to 74)	4 (4 to 18)
CD40L-/IL2+/TNFa+/IFNg+, D30 (N=5;2;16;16;34;34)	4 (4 to 41)	26 (4 to 48)	35 (4 to 85)	4 (4 to 10.5)

CD40L-/IL2+/TNFa+/IFNg+, D37 (N=5;3;18;19;34;34)	89 (46 to 93)	4 (4 to 4)	64.5 (17 to 148)	4 (4 to 4)
CD40L-/IL2+/TNFa+/IFNg+, D60 (N=4;2;15;18;31;32)	39.5 (17.5 to 62.5)	4 (4 to 4)	4 (4 to 60)	4 (4 to 4)
CD40L-/IL2+/TNFa+/IFNg+, D210 (N=6;3;13;17;37;36)	19 (4 to 32)	4 (4 to 4)	4 (4 to 19)	4 (4 to 4)
CD40L-/IL2+/TNFa+/IFNg-, PRE (N=4;3;15;22;30;30)	4 (4 to 11)	4 (4 to 4)	4 (4 to 20)	4 (4 to 4)
CD40L-/IL2+/TNFa+/IFNg-, D7 (N=4;3;13;15;26;28)	4 (4 to 4)	4 (4 to 4)	4 (4 to 4)	4 (4 to 4)
CD40L-/IL2+/TNFa+/IFNg-, D30 (N=5;2;16;16;34;34)	17 (4 to 17)	4 (4 to 4)	19.5 (4 to 54.5)	4 (4 to 17.5)
CD40L-/IL2+/TNFa+/IFNg-, D37 (N=5;3;18;19;34;34)	4 (4 to 4)	4 (4 to 4)	4 (4 to 24)	4 (4 to 4)
CD40L-/IL2+/TNFa+/IFNg-, D60 (N=4;2;15;18;31;32)	21 (10.5 to 55.5)	4 (4 to 4)	4 (4 to 19)	4 (4 to 4)
CD40L-/IL2+/TNFa+/IFNg-, D210 (N=6;3;13;17;37;36)	4 (4 to 21)	17 (4 to 18)	4 (4 to 4)	4 (4 to 4)

End point values	TB Naive GSK 692342 Group	TB Naive Saline Group		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	37	36		
Units: T cells/million cells				
median (inter-quartile range (Q1-Q3))				
CD40L-/IL2+/TNFa+/IFNg+, PRE (N=4;3;15;22;30;30)	4 (4 to 4)	4 (4 to 4)		
CD40L-/IL2+/TNFa+/IFNg+, D7 (N=4;3;13;15;26;28)	4 (4 to 26)	4 (4 to 4)		
CD40L-/IL2+/TNFa+/IFNg+, D30 (N=5;2;16;16;34;34)	4 (4 to 25)	4 (4 to 19)		
CD40L-/IL2+/TNFa+/IFNg+, D37 (N=5;3;18;19;34;34)	32.5 (4 to 66)	4 (4 to 4)		
CD40L-/IL2+/TNFa+/IFNg+, D60 (N=4;2;15;18;31;32)	19 (4 to 33)	4 (4 to 4)		
CD40L-/IL2+/TNFa+/IFNg+, D210 (N=6;3;13;17;37;36)	4 (4 to 31)	4 (4 to 4)		
CD40L-/IL2+/TNFa+/IFNg-, PRE (N=4;3;15;22;30;30)	4 (4 to 4)	4 (4 to 4)		
CD40L-/IL2+/TNFa+/IFNg-, D7 (N=4;3;13;15;26;28)	4 (4 to 4)	4 (4 to 4)		
CD40L-/IL2+/TNFa+/IFNg-, D30 (N=5;2;16;16;34;34)	17.5 (4 to 33)	4 (4 to 4)		
CD40L-/IL2+/TNFa+/IFNg-, D37 (N=5;3;18;19;34;34)	34 (8 to 67)	4 (4 to 4)		
CD40L-/IL2+/TNFa+/IFNg-, D60 (N=4;2;15;18;31;32)	45 (16 to 79)	4 (4 to 4)		
CD40L-/IL2+/TNFa+/IFNg-, D210 (N=6;3;13;17;37;36)	4 (4 to 34)	4 (4 to 10.5)		

## Statistical analyses

No statistical analyses for this end point



**Secondary: Frequency of M72-specific CD4+ T cells per million cells expressing any combination of immune markers.**

End point title	Frequency of M72-specific CD4+ T cells per million cells expressing any combination of immune markers.
End point description: Immune markers expressed were among Interleukin-2 (IL-2), Interferon-gamma (IFN-g), Tumour necrosis factor-alpha (TNF-a) and/or CD40-ligand (CD40-L).	
End point type	Secondary
End point timeframe: Prior to dose 1 (Day 0 - PRE), post-dose 1 (Days 7 - D7 and 30 - D30), post-dose 2 (Days 37 - D37, 60 - D60 and 210 - D210)	

End point values	TB Treatment GSK 692342 Group	TB Treatment Saline Group	TB Treated GSK 692342 Group	TB Treated Saline Group
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	6	3	18	22
Units: T cells/million cells				
median (inter-quartile range (Q1-Q3))				
CD40L-/IL2+/TNFa-/IFNg+, PRE (N=4;3;15;22;30;30)	4 (4 to 4)	4 (4 to 4)	4 (4 to 4)	4 (4 to 4)
CD40L-/IL2+/TNFa-/IFNg+, D7 (N=4;3;13;15;26;28)	4 (4 to 16.5)	4 (4 to 4)	17 (4 to 18)	4 (4 to 4)
CD40L-/IL2+/TNFa-/IFNg+, D30 (N=5;2;16;16;34;34)	4 (4 to 4)	4 (4 to 4)	11 (4 to 23.5)	4 (4 to 4)
CD40L-/IL2+/TNFa-/IFNg+, D37 (N=5;3;18;19;34;34)	17 (17 to 32)	4 (4 to 4)	17 (4 to 24)	4 (4 to 4)
CD40L-/IL2+/TNFa-/IFNg+, D60 (N=4;2;15;18;31;32)	4 (4 to 4)	4 (4 to 4)	4 (4 to 20)	4 (4 to 4)
CD40L-/IL2+/TNFa-/IFNg+, D210 (N=6;3;13;17;37;36)	4 (4 to 24)	4 (4 to 4)	4 (4 to 4)	4 (4 to 4)
CD40L-/IL2+/TNFa-/IFNg-, PRE (N=4;3;15;22;30;30)	4 (4 to 10.5)	4 (4 to 20)	4 (4 to 23)	4 (4 to 18)
CD40L-/IL2+/TNFa-/IFNg-, D7 (N=4;3;13;15;26;28)	4 (4 to 18)	4 (4 to 17)	4 (4 to 17)	17 (4 to 30)
CD40L-/IL2+/TNFa-/IFNg-, D30 (N=5;2;16;16;34;34)	30 (19 to 32)	4 (4 to 4)	21 (6.5 to 44.5)	4 (4 to 19)
CD40L-/IL2+/TNFa-/IFNg-, D37 (N=5;3;18;19;34;34)	4 (4 to 4)	4 (4 to 4)	27.5 (17 to 45)	4 (4 to 5)
CD40L-/IL2+/TNFa-/IFNg-, D60 (N=4;2;15;18;31;32)	11 (4.5 to 28.5)	17.5 (4 to 31)	4 (4 to 20)	11 (4 to 23)
CD40L-/IL2+/TNFa-/IFNg-, D210 (N=6;3;13;17;37;36)	17.5 (4 to 59)	4 (4 to 32)	4 (4 to 17)	4 (4 to 26)

End point values	TB Naive GSK 692342 Group	TB Naive Saline Group		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	37	36		
Units: T cells/million cells				
median (inter-quartile range (Q1-Q3))				
CD40L-/IL2+/TNFa-/IFNg+, PRE (N=4;3;15;22;30;30)	4 (4 to 4)	4 (4 to 4)		

CD40L-/IL2+/TNFa-/IFNg+, D7 (N=4;3;13;15;26;28)	4 (4 to 19)	4 (4 to 4)		
CD40L-/IL2+/TNFa-/IFNg+, D30 (N=5;2;16;16;34;34)	4 (4 to 4)	4 (4 to 4)		
CD40L-/IL2+/TNFa-/IFNg+, D37 (N=5;3;18;19;34;34)	19.5 (4 to 61)	4 (4 to 4)		
CD40L-/IL2+/TNFa-/IFNg+, D60 (N=4;2;15;18;31;32)	4 (4 to 22)	4 (4 to 4)		
CD40L-/IL2+/TNFa-/IFNg+, D210 (N=6;3;13;17;37;36)	4 (4 to 4)	4 (4 to 4)		
CD40L-/IL2+/TNFa-/IFNg-, PRE (N=4;3;15;22;30;30)	4 (4 to 4)	4 (4 to 21)		
CD40L-/IL2+/TNFa-/IFNg-, D7 (N=4;3;13;15;26;28)	18.5 (4 to 26)	4 (4 to 12)		
CD40L-/IL2+/TNFa-/IFNg-, D30 (N=5;2;16;16;34;34)	18 (4 to 32)	4 (4 to 20)		
CD40L-/IL2+/TNFa-/IFNg-, D37 (N=5;3;18;19;34;34)	40.5 (19 to 82)	4 (4 to 20)		
CD40L-/IL2+/TNFa-/IFNg-, D60 (N=4;2;15;18;31;32)	49 (20 to 70)	4 (4 to 18)		
CD40L-/IL2+/TNFa-/IFNg-, D210 (N=6;3;13;17;37;36)	25 (8 to 44)	4 (4 to 19.5)		

## Statistical analyses

No statistical analyses for this end point

## Secondary: Frequency of M72-specific CD4+ T cells per million cells expressing any combination of immune markers.

End point title	Frequency of M72-specific CD4+ T cells per million cells expressing any combination of immune markers.
End point description: Immune markers expressed were among Interleukin-2 (IL-2), Interferon-gamma (IFN-g), Tumour necrosis factor-alpha (TNF-a) and/or CD40-ligand (CD40-L).	
End point type	Secondary
End point timeframe: Prior to dose 1 (Day 0 - PRE), post-dose 1 (Days 7 – D7 and 30 – D30), post-dose 2 (Days 37 – D37, 60 – D60 and 210 – D210)	

End point values	TB Treatment GSK 692342 Group	TB Treatment Saline Group	TB Treated GSK 692342 Group	TB Treated Saline Group
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	6	3	18	22
Units: T cells/million cells				
median (inter-quartile range (Q1-Q3))				
CD40L-/IL2-/TNFa+/IFNg+, PRE (N=4;3;15;22;30;30)	10.5 (4 to 25)	4 (4 to 4)	24 (4 to 59)	13.5 (4 to 136)
CD40L-/IL2-/TNFa+/IFNg+, D7 (N=4;3;13;15;26;28)	53.5 (34.5 to 87.5)	4 (4 to 17)	102 (40 to 230)	18 (4 to 234)
CD40L-/IL2-/TNFa+/IFNg+, D30 (N=5;2;16;16;34;34)	76 (4 to 117)	26 (4 to 48)	112 (21.5 to 212)	44 (10.5 to 334.5)

CD40L-/IL2-/TNFa+/IFNg+, D37 (N=5;3;18;19;34;34)	246 (116 to 288)	34 (4 to 65)	212.5 (94 to 698)	50 (5 to 361)
CD40L-/IL2-/TNFa+/IFNg+, D60 (N=4;2;15;18;31;32)	162.5 (76 to 214)	14 (4 to 24)	34 (19 to 338)	46 (4 to 534)
CD40L-/IL2-/TNFa+/IFNg+, D210 (N=6;3;13;17;37;36)	19.5 (4 to 156)	4 (4 to 18)	30 (18 to 112)	29 (4 to 169)
CD40L-/IL2-/TNFa+/IFNg-, PRE (N=4;3;15;22;30;30)	11.5 (5 to 31)	18 (18 to 29)	20 (4 to 55)	4 (4 to 41)
CD40L-/IL2-/TNFa+/IFNg-, D7 (N=4;3;13;15;26;28)	25.5 (11 to 38)	17 (4 to 45)	19 (4 to 75)	17 (4 to 32)
CD40L-/IL2-/TNFa+/IFNg-, D30 (N=5;2;16;16;34;34)	21 (6 to 26)	4 (4 to 4)	51.5 (15 to 101)	32.5 (4.5 to 67)
CD40L-/IL2-/TNFa+/IFNg-, D37 (N=5;3;18;19;34;34)	46 (31 to 153)	66 (31 to 117)	87 (31 to 256)	11 (4 to 119)
CD40L-/IL2-/TNFa+/IFNg-, D60 (N=4;2;15;18;31;32)	67 (57.5 to 108)	50 (40 to 60)	23 (4 to 104)	36 (4 to 59)
CD40L-/IL2-/TNFa+/IFNg-, D210 (N=6;3;13;17;37;36)	4 (4 to 60)	4 (4 to 4)	5 (4 to 57)	23 (4 to 54)

End point values	TB Naive GSK 692342 Group	TB Naive Saline Group		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	37	36		
Units: T cells/million cells				
median (inter-quartile range (Q1-Q3))				
CD40L-/IL2-/TNFa+/IFNg+, PRE (N=4;3;15;22;30;30)	17.5 (4 to 32)	4 (4 to 57)		
CD40L-/IL2-/TNFa+/IFNg+, D7 (N=4;3;13;15;26;28)	53 (17 to 246)	4 (4 to 53)		
CD40L-/IL2-/TNFa+/IFNg+, D30 (N=5;2;16;16;34;34)	42 (4 to 89)	20 (4 to 46)		
CD40L-/IL2-/TNFa+/IFNg+, D37 (N=5;3;18;19;34;34)	185.5 (61 to 463)	4 (4 to 33)		
CD40L-/IL2-/TNFa+/IFNg+, D60 (N=4;2;15;18;31;32)	69 (32 to 277)	18.5 (4 to 45.5)		
CD40L-/IL2-/TNFa+/IFNg+, D210 (N=6;3;13;17;37;36)	46 (4 to 77)	11.5 (4 to 38)		
CD40L-/IL2-/TNFa+/IFNg-, PRE (N=4;3;15;22;30;30)	8 (4 to 38)	22.5 (4 to 68)		
CD40L-/IL2-/TNFa+/IFNg-, D7 (N=4;3;13;15;26;28)	26 (4 to 57)	28.5 (4 to 81.5)		
CD40L-/IL2-/TNFa+/IFNg-, D30 (N=5;2;16;16;34;34)	8 (4 to 61)	12.5 (4 to 31)		
CD40L-/IL2-/TNFa+/IFNg-, D37 (N=5;3;18;19;34;34)	309 (137 to 532)	7.5 (4 to 26)		
CD40L-/IL2-/TNFa+/IFNg-, D60 (N=4;2;15;18;31;32)	88 (35 to 225)	22 (4 to 44)		
CD40L-/IL2-/TNFa+/IFNg-, D210 (N=6;3;13;17;37;36)	24 (4 to 76)	4 (4 to 34.5)		

## Statistical analyses

No statistical analyses for this end point

**Secondary: Frequency of M72-specific CD4+ T cells per million cells expressing any combination of immune markers.**

End point title	Frequency of M72-specific CD4+ T cells per million cells expressing any combination of immune markers.
End point description: Immune markers expressed were among Interleukin-2 (IL-2), Interferon-gamma (IFN-g), Tumour necrosis factor-alpha (TNF-a) and/or CD40-ligand (CD40-L).	
End point type	Secondary
End point timeframe: Prior to dose 1 (Day 0 - PRE), post-dose 1 (Days 7 - D7 and 30 - D30), post-dose 2 (Days 37 - D37, 60 - D60 and 210 - D210)	

End point values	TB Treatment GSK 692342 Group	TB Treatment Saline Group	TB Treated GSK 692342 Group	TB Treated Saline Group
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	6	3	18	22
Units: T cells/million cells				
median (inter-quartile range (Q1-Q3))				
CD40L-/IL2-/TNFa-/IFNg+, PRE (N=4;3;15;22;30;30)	17.5 (4 to 52.5)	20 (4 to 61)	47 (4 to 64)	51 (4 to 99)
CD40L-/IL2-/TNFa-/IFNg+, D7 (N=4;3;13;15;26;28)	69.5 (17.5 to 114)	4 (4 to 83)	59 (12 to 363)	46 (6 to 482)
CD40L-/IL2-/TNFa-/IFNg+, D30 (N=5;2;16;16;34;34)	45 (45 to 61)	4 (4 to 4)	52 (4 to 201.5)	33.5 (4 to 270)
CD40L-/IL2-/TNFa-/IFNg+, D37 (N=5;3;18;19;34;34)	191 (89 to 408)	34 (31 to 97)	273 (131 to 720)	27 (4 to 261)
CD40L-/IL2-/TNFa-/IFNg+, D60 (N=4;2;15;18;31;32)	14.5 (4 to 48.5)	4 (4 to 4)	32 (4 to 267)	51.5 (17 to 144)
CD40L-/IL2-/TNFa-/IFNg+, D210 (N=6;3;13;17;37;36)	53.5 (31 to 117)	4 (4 to 60)	30 (4 to 85)	34 (4 to 92)

End point values	TB Naive GSK 692342 Group	TB Naive Saline Group		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	37	36		
Units: T cells/million cells				
median (inter-quartile range (Q1-Q3))				
CD40L-/IL2-/TNFa-/IFNg+, PRE (N=4;3;15;22;30;30)	70 (38 to 157)	14.5 (4 to 85)		
CD40L-/IL2-/TNFa-/IFNg+, D7 (N=4;3;13;15;26;28)	78 (32 to 248)	25.5 (4 to 76)		
CD40L-/IL2-/TNFa-/IFNg+, D30 (N=5;2;16;16;34;34)	47 (4 to 138)	26.5 (4 to 132)		
CD40L-/IL2-/TNFa-/IFNg+, D37 (N=5;3;18;19;34;34)	495.5 (267 to 1466)	19 (4 to 86)		
CD40L-/IL2-/TNFa-/IFNg+, D60 (N=4;2;15;18;31;32)	129 (40 to 276)	19.5 (4 to 84)		
CD40L-/IL2-/TNFa-/IFNg+, D210 (N=6;3;13;17;37;36)	31 (4 to 126)	55 (32.5 to 115)		

## Statistical analyses

No statistical analyses for this end point

### Secondary: Frequency of M72-specific CD8+ T cells per million cells expressing at least 2 immune markers.

End point title	Frequency of M72-specific CD8+ T cells per million cells expressing at least 2 immune markers.
End point description: Immune markers expressed were among Interleukin-2 (IL-2), Interferon-gamma (IFN-g), Tumour necrosis factor-alpha (TNF-a) and/or CD40-ligand (CD40-L).	
End point type	Secondary
End point timeframe: Prior to dose 1 (Day 0 - PRE), post-dose 1 (Days 7 - D7 and 30 - D30), post-dose 2 (Days 37 - D37, 60 - D60 and 210 - D210)	

End point values	TB Treatment GSK 692342 Group	TB Treatment Saline Group	TB Treated GSK 692342 Group	TB Treated Saline Group
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	6	3	18	22
Units: T cells/million cells				
median (inter-quartile range (Q1-Q3))				
CD8-ALL doubles, PRE (N=4; 3; 15; 22; 30; 30)	93 (63.5 to 269)	44 (44 to 135)	99 (75 to 159)	110.5 (59 to 326)
CD8-ALL doubles, D7 (N=4; 3; 13; 15; 26; 28)	94.5 (80.5 to 141)	72 (45 to 77)	222 (146 to 329)	62 (44 to 324)
CD8-ALL doubles, D30 (N=5; 2; 16; 16; 34; 34)	44 (44 to 64)	81.5 (44 to 119)	243 (101 to 385)	153.5 (75.5 to 1064)
CD8-ALL doubles, D37 (N=5; 3; 18; 19; 34; 34)	126 (118 to 134)	76 (44 to 93)	347 (97 to 604)	108 (59 to 295)
CD8-ALL doubles, D60 (N=4; 2; 15; 18; 31; 32)	85.5 (55.5 to 233)	118 (69 to 167)	189 (60 to 367)	161 (84 to 491)
CD8-ALL doubles, D210 (N=6; 3; 13; 17; 37; 36)	347.5 (170 to 572)	78 (44 to 91)	259 (61 to 312)	119 (44 to 390)

End point values	TB Naive GSK 692342 Group	TB Naive Saline Group		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	37	36		
Units: T cells/million cells				
median (inter-quartile range (Q1-Q3))				
CD8-ALL doubles, PRE (N=4; 3; 15; 22; 30; 30)	73 (44 to 144)	69.5 (44 to 132)		

CD8-ALL doubles, D7 (N=4; 3; 13; 15; 26; 28)	74.5 (44 to 144)	92.5 (53 to 191)		
CD8-ALL doubles, D30 (N=5; 2; 16; 16; 34; 34)	80 (44 to 150)	77.5 (59 to 172)		
CD8-ALL doubles, D37 (N=5; 3; 18; 19; 34; 34)	72.5 (57 to 149)	75.5 (44 to 140)		
CD8-ALL doubles, D60 (N=4; 2; 15; 18; 31; 32)	96 (44 to 245)	71 (44 to 157.5)		
CD8-ALL doubles, D210 (N=6; 3; 13; 17; 37; 36)	110 (69 to 248)	71.5 (49.5 to 233)		

## Statistical analyses

No statistical analyses for this end point

## Secondary: Frequency of M72-specific CD8+ T cells per million cells expressing 2 or more immune markers among 6.

End point title	Frequency of M72-specific CD8+ T cells per million cells expressing 2 or more immune markers among 6.
-----------------	---

End point description:

Immune markers expressed were among Interleukin-2 (IL-2), Interferon-gamma (IFN-g), Tumour necrosis factor-alpha (TNF-a), CD40-ligand (CD40-L), Interleukin-17 (IL-17) and/or Interleukin-17 (IL-17).

End point type	Secondary
----------------	-----------

End point timeframe:

Prior to dose 1 (Day 0 - PRE), post-dose 1 (Days 7 - D7 and 30 - D30), post-dose 2 (Days 37 - D37, 60 - D60 and 210 - D210)

End point values	TB Treatment GSK 692342 Group	TB Treatment Saline Group	TB Treated GSK 692342 Group	TB Treated Saline Group
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	6	3	18	22
Units: T cells/million cells				
median (inter-quartile range (Q1-Q3))				
CD8-At least 2, PRE (N=4; 3; 15; 22; 30; 30)	106 (76.5 to 282)	57 (57 to 148)	143 (88 to 172)	151.5 (81 to 339)
CD8- At least 2, D7 (N=4; 3; 13; 15; 26; 28)	107.5 (93.5 to 154)	85 (58 to 90)	245 (159 to 369)	75 (57 to 337)
CD8- At least 2, D30 (N=5; 2; 16; 16; 34; 34)	57 (57 to 77)	109 (86 to 132)	256 (114 to 410.5)	166.5 (88.5 to 1077)
CD8- At least 2, D37 (N=5; 3; 18; 19; 34; 34)	139 (131 to 147)	89 (57 to 106)	362 (110 to 617)	121 (72 to 308)
CD8- At least 2, D60 (N=4; 2; 15; 18; 31; 32)	98.5 (68.5 to 246)	131 (82 to 180)	202 (89 to 380)	174 (97 to 504)
CD8- At least 2, D210 (N=6; 3; 13; 17; 37; 36)	403.5 (183 to 585)	91 (57 to 151)	272 (74 to 379)	133 (76 to 403)

End point values	TB Naive GSK 692342 Group	TB Naive Saline Group		
------------------	---------------------------	-----------------------	--	--

Subject group type	Reporting group	Reporting group		
Number of subjects analysed	37	36		
Units: T cells/million cells				
median (inter-quartile range (Q1-Q3))				
CD8-At least 2, PRE (N=4; 3; 15; 22; 30; 30)	96 (57 to 157)	85.5 (57 to 169)		
CD8- At least 2, D7 (N=4; 3; 13; 15; 26; 28)	116 (71 to 158)	124 (88 to 232)		
CD8- At least 2, D30 (N=5; 2; 16; 16; 34; 34)	96 (73 to 163)	106.5 (77 to 198)		
CD8- At least 2, D37 (N=5; 3; 18; 19; 34; 34)	85.5 (70 to 162)	103.5 (58 to 161)		
CD8- At least 2, D60 (N=4; 2; 15; 18; 31; 32)	111 (76 to 270)	106.5 (57 to 191)		
CD8- At least 2, D210 (N=6; 3; 13; 17; 37; 36)	137 (83 to 291)	124.5 (81.5 to 292)		

## Statistical analyses

No statistical analyses for this end point

### Secondary: Frequency of M72-specific CD8+ T cells per million cells expressing any combination of immune markers.

End point title	Frequency of M72-specific CD8+ T cells per million cells expressing any combination of immune markers.
-----------------	--

End point description:

Immune markers expressed were among Interleukin-2 (IL-2), Interferon-gamma (IFN-g), Tumour necrosis factor-alpha (TNF-a) and/or CD40-ligand (CD40-L).

End point type	Secondary
----------------	-----------

End point timeframe:

Prior to dose 1 (Day 0 - PRE), post-dose 1 (Days 7 - D7 and 30 - D30), post-dose 2 (Days 37 - D37, 60 - D60 and 210 - D210)

End point values	TB Treatment GSK 692342 Group	TB Treatment Saline Group	TB Treated GSK 692342 Group	TB Treated Saline Group
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	6	3	18	22
Units: T cells/million cells				
median (inter-quartile range (Q1-Q3))				
CD40L+/IL2+/TNFa+/IFNg+, PRE (N=4;3;15;22;30;30)	4 (4 to 4)	4 (4 to 4)	4 (4 to 4)	4 (4 to 4)
CD40L+/IL2+/TNFa+/IFNg+, D7 (N=4;3;13;15;26;28)	4 (4 to 14)	4 (4 to 4)	4 (4 to 62)	4 (4 to 4)
CD40L+/IL2+/TNFa+/IFNg+, D30 (N=5;2;16;16;34;34)	4 (4 to 4)	4 (4 to 4)	4 (4 to 25)	4 (4 to 4)
CD40L+/IL2+/TNFa+/IFNg+, D37 (N=5;3;18;19;34;34)	4 (4 to 41)	4 (4 to 4)	4 (4 to 48)	4 (4 to 4)
CD40L+/IL2+/TNFa+/IFNg+, D60 (N=4;2;15;18;31;32)	4 (4 to 4)	4 (4 to 4)	4 (4 to 4)	4 (4 to 4)
CD40L+/IL2+/TNFa+/IFNg+, D210 (N=6;3;13;17;37;36)	58 (4 to 99)	4 (4 to 38)	4 (4 to 4)	4 (4 to 33)

CD40L+/IL2+/TNFa+/IFNg-, PRE (N=4;3;15;22;30;30)	4 (4 to 4)	4 (4 to 4)	4 (4 to 4)	4 (4 to 4)
CD40L+/IL2+/TNFa+/IFNg-, D7 (N=4;3;13;15;26;28)	4 (4 to 4)	4 (4 to 4)	4 (4 to 4)	4 (4 to 4)
CD40L+/IL2+/TNFa+/IFNg-, D30 (N=5;2;16;16;34;34)	4 (4 to 4)	4 (4 to 4)	4 (4 to 4)	4 (4 to 4)
CD40L+/IL2+/TNFa+/IFNg-, D37 (N=5;3;18;19;34;34)	4 (4 to 4)	4 (4 to 4)	4 (4 to 4)	4 (4 to 4)
CD40L+/IL2+/TNFa+/IFNg-, D60 (N=4;2;15;18;31;32)	4 (4 to 19)	4 (4 to 4)	4 (4 to 4)	4 (4 to 4)
CD40L+/IL2+/TNFa+/IFNg-, D210 (N=6;3;13;17;37;36)	35 (4 to 46)	4 (4 to 4)	4 (4 to 4)	4 (4 to 4)

End point values	TB Naive GSK 692342 Group	TB Naive Saline Group		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	37	36		
Units: T cells/million cells				
median (inter-quartile range (Q1-Q3))				
CD40L+/IL2+/TNFa+/IFNg+, PRE (N=4;3;15;22;30;30)	4 (4 to 4)	4 (4 to 4)		
CD40L+/IL2+/TNFa+/IFNg+, D7 (N=4;3;13;15;26;28)	4 (4 to 4)	4 (4 to 4)		
CD40L+/IL2+/TNFa+/IFNg+, D30 (N=5;2;16;16;34;34)	4 (4 to 4)	4 (4 to 4)		
CD40L+/IL2+/TNFa+/IFNg+, D37 (N=5;3;18;19;34;34)	4 (4 to 4)	4 (4 to 4)		
CD40L+/IL2+/TNFa+/IFNg+, D60 (N=4;2;15;18;31;32)	4 (4 to 4)	4 (4 to 4)		
CD40L+/IL2+/TNFa+/IFNg+, D210 (N=6;3;13;17;37;36)	4 (4 to 4)	4 (4 to 4)		
CD40L+/IL2+/TNFa+/IFNg-, PRE (N=4;3;15;22;30;30)	4 (4 to 4)	4 (4 to 4)		
CD40L+/IL2+/TNFa+/IFNg-, D7 (N=4;3;13;15;26;28)	4 (4 to 4)	4 (4 to 4)		
CD40L+/IL2+/TNFa+/IFNg-, D30 (N=5;2;16;16;34;34)	4 (4 to 4)	4 (4 to 4)		
CD40L+/IL2+/TNFa+/IFNg-, D37 (N=5;3;18;19;34;34)	4 (4 to 4)	4 (4 to 4)		
CD40L+/IL2+/TNFa+/IFNg-, D60 (N=4;2;15;18;31;32)	4 (4 to 4)	4 (4 to 4)		
CD40L+/IL2+/TNFa+/IFNg-, D210 (N=6;3;13;17;37;36)	4 (4 to 25)	4 (4 to 4)		

## Statistical analyses

No statistical analyses for this end point

## Secondary: Frequency of M72-specific CD8+ T cells per million cells expressing any combination of immune markers.

End point title	Frequency of M72-specific CD8+ T cells per million cells expressing any combination of immune markers.
-----------------	--



End point description:

Immune markers expressed were among Interleukin-2 (IL-2), Interferon-gamma (IFN-g), Tumour necrosis factor-alpha (TNF-a) and/or CD40-ligand (CD40-L).

End point type Secondary

End point timeframe:

Prior to dose 1 (Day 0 - PRE), post-dose 1 (Days 7 - D7 and 30 - D30), post-dose 2 (Days 37 - D37, 60 - D60 and 210 - D210)

End point values	TB Treatment GSK 692342 Group	TB Treatment Saline Group	TB Treated GSK 692342 Group	TB Treated Saline Group
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	6	3	18	22
Units: T cells/million cells				
median (inter-quartile range (Q1-Q3))				
CD40L+/IL2+/TNFa-/IFNg+, PRE (N=4;3;15;22;30;30)	4 (4 to 4)	4 (4 to 4)	4 (4 to 4)	4 (4 to 4)
CD40L+/IL2+/TNFa-/IFNg+, D7 (N=4;3;13;15;26;28)	4 (4 to 4)	4 (4 to 4)	4 (4 to 4)	4 (4 to 4)
CD40L+/IL2+/TNFa-/IFNg+, D30 (N=5;2;16;16;34;34)	4 (4 to 4)	4 (4 to 4)	4 (4 to 4)	4 (4 to 4)
CD40L+/IL2+/TNFa-/IFNg+, D37 (N=5;3;18;19;34;34)	4 (4 to 4)	4 (4 to 4)	4 (4 to 4)	4 (4 to 4)
CD40L+/IL2+/TNFa-/IFNg+, D60 (N=4;2;15;18;31;32)	4 (4 to 4)	4 (4 to 4)	4 (4 to 4)	4 (4 to 4)
CD40L+/IL2+/TNFa-/IFNg+, D210 (N=6;3;13;17;37;36)	4 (4 to 4)	4 (4 to 4)	4 (4 to 4)	4 (4 to 4)
CD40L+/IL2+/TNFa-/IFNg-, PRE (N=4;3;15;22;30;30)	4 (4 to 4)	4 (4 to 4)	4 (4 to 4)	4 (4 to 4)
CD40L+/IL2+/TNFa-/IFNg-, D7 (N=4;3;13;15;26;28)	4 (4 to 4)	4 (4 to 32)	4 (4 to 4)	4 (4 to 4)
CD40L+/IL2+/TNFa-/IFNg-, D30 (N=5;2;16;16;34;34)	4 (4 to 4)	4 (4 to 4)	4 (4 to 4)	4 (4 to 4)
CD40L+/IL2+/TNFa-/IFNg-, D37 (N=5;3;18;19;34;34)	4 (4 to 4)	4 (4 to 4)	4 (4 to 4)	4 (4 to 4)
CD40L+/IL2+/TNFa-/IFNg-, D60 (N=4;2;15;18;31;32)	4 (4 to 4)	14 (4 to 24)	4 (4 to 4)	4 (4 to 4)
CD40L+/IL2+/TNFa-/IFNg-, D210 (N=6;3;13;17;37;36)	4 (4 to 4)	4 (4 to 4)	4 (4 to 4)	4 (4 to 4)

End point values	TB Naive GSK 692342 Group	TB Naive Saline Group		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	37	36		
Units: T cells/million cells				
median (inter-quartile range (Q1-Q3))				
CD40L+/IL2+/TNFa-/IFNg+, PRE (N=4;3;15;22;30;30)	4 (4 to 4)	4 (4 to 4)		
CD40L+/IL2+/TNFa-/IFNg+, D7 (N=4;3;13;15;26;28)	4 (4 to 4)	4 (4 to 4)		
CD40L+/IL2+/TNFa-/IFNg+, D30 (N=5;2;16;16;34;34)	4 (4 to 4)	4 (4 to 4)		

CD40L+/IL2+/TNFa-/IFNg+, D37 (N=5;3;18;19;34;34)	4 (4 to 4)	4 (4 to 4)		
CD40L+/IL2+/TNFa-/IFNg+, D60 (N=4;2;15;18;31;32)	4 (4 to 4)	4 (4 to 4)		
CD40L+/IL2+/TNFa-/IFNg+, D210 (N=6;3;13;17;37;36)	4 (4 to 4)	4 (4 to 4)		
CD40L+/IL2+/TNFa-/IFNg-, PRE (N=4;3;15;22;30;30)	4 (4 to 4)	4 (4 to 4)		
CD40L+/IL2+/TNFa-/IFNg-, D7 (N=4;3;13;15;26;28)	4 (4 to 4)	4 (4 to 4)		
CD40L+/IL2+/TNFa-/IFNg-, D30 (N=5;2;16;16;34;34)	4 (4 to 4)	4 (4 to 4)		
CD40L+/IL2+/TNFa-/IFNg-, D37 (N=5;3;18;19;34;34)	4 (4 to 4)	4 (4 to 4)		
CD40L+/IL2+/TNFa-/IFNg-, D60 (N=4;2;15;18;31;32)	4 (4 to 4)	4 (4 to 4)		
CD40L+/IL2+/TNFa-/IFNg-, D210 (N=6;3;13;17;37;36)	4 (4 to 4)	4 (4 to 4)		

## Statistical analyses

No statistical analyses for this end point

## Secondary: Frequency of M72-specific CD8+ T cells per million cells expressing any combination of immune markers.

End point title	Frequency of M72-specific CD8+ T cells per million cells expressing any combination of immune markers.
End point description: Immune markers expressed were among Interleukin-2 (IL-2), Interferon-gamma (IFN-g), Tumour necrosis factor-alpha (TNF-a) and/or CD40-ligand (CD40-L).	
End point type	Secondary
End point timeframe: Prior to dose 1 (Day 0 - PRE), post-dose 1 (Days 7 - D7 and 30 - D30), post-dose 2 (Days 37 - D37, 60 - D60 and 210 - D210)	

End point values	TB Treatment GSK 692342 Group	TB Treatment Saline Group	TB Treated GSK 692342 Group	TB Treated Saline Group
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	6	3	18	22
Units: T cells/million cells				
median (inter-quartile range (Q1-Q3))				
CD40L+/IL2-/TNFa+/IFNg+, PRE (N=4;3;15;22;30;30)	4 (4 to 33.5)	4 (4 to 4)	4 (4 to 4)	4 (4 to 23)
CD40L+/IL2-/TNFa+/IFNg+, D7 (N=4;3;13;15;26;28)	4 (4 to 4)	4 (4 to 4)	4 (4 to 55)	4 (4 to 4)
CD40L+/IL2-/TNFa+/IFNg+, D30 (N=5;2;16;16;34;34)	4 (4 to 4)	4 (4 to 4)	36.5 (4 to 84)	4 (4 to 4)
CD40L+/IL2-/TNFa+/IFNg+, D37 (N=5;3;18;19;34;34)	4 (4 to 4)	4 (4 to 4)	4 (4 to 168)	4 (4 to 21)
CD40L+/IL2-/TNFa+/IFNg+, D60 (N=4;2;15;18;31;32)	4 (4 to 4)	4 (4 to 4)	4 (4 to 42)	4 (4 to 24)

CD40L+/IL2-/TNFa+/IFNg+, D210 (N=6;3;13;17;37;36)	4 (4 to 13)	4 (4 to 51)	4 (4 to 56)	4 (4 to 4)
CD40L+/IL2-/TNFa+/IFNg-, PRE (N=4;3;15;22;30;30)	4 (4 to 4)	4 (4 to 4)	4 (4 to 4)	4 (4 to 4)
CD40L+/IL2-/TNFa+/IFNg-, D7 (N=4;3;13;15;26;28)	4 (4 to 4)	4 (4 to 37)	4 (4 to 4)	4 (4 to 4)
CD40L+/IL2-/TNFa+/IFNg-, D30 (N=5;2;16;16;34;34)	4 (4 to 4)	4 (4 to 4)	4 (4 to 4)	4 (4 to 17)
CD40L+/IL2-/TNFa+/IFNg-, D37 (N=5;3;18;19;34;34)	4 (4 to 4)	4 (4 to 4)	4 (4 to 4)	4 (4 to 4)
CD40L+/IL2-/TNFa+/IFNg-, D60 (N=4;2;15;18;31;32)	4 (4 to 21)	24.5 (4 to 45)	4 (4 to 20)	4 (4 to 4)
CD40L+/IL2-/TNFa+/IFNg-, D210 (N=6;3;13;17;37;36)	4 (4 to 4)	4 (4 to 4)	4 (4 to 21)	4 (4 to 4)

End point values	TB Naive GSK 692342 Group	TB Naive Saline Group		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	37	36		
Units: T cells/million cells				
median (inter-quartile range (Q1-Q3))				
CD40L+/IL2-/TNFa+/IFNg+, PRE (N=4;3;15;22;30;30)	4 (4 to 4)	4 (4 to 4)		
CD40L+/IL2-/TNFa+/IFNg+, D7 (N=4;3;13;15;26;28)	4 (4 to 4)	4 (4 to 4)		
CD40L+/IL2-/TNFa+/IFNg+, D30 (N=5;2;16;16;34;34)	4 (4 to 4)	4 (4 to 4)		
CD40L+/IL2-/TNFa+/IFNg+, D37 (N=5;3;18;19;34;34)	4 (4 to 4)	4 (4 to 4)		
CD40L+/IL2-/TNFa+/IFNg+, D60 (N=4;2;15;18;31;32)	4 (4 to 4)	4 (4 to 4)		
CD40L+/IL2-/TNFa+/IFNg+, D210 (N=6;3;13;17;37;36)	4 (4 to 21)	4 (4 to 4)		
CD40L+/IL2-/TNFa+/IFNg-, PRE (N=4;3;15;22;30;30)	4 (4 to 4)	4 (4 to 4)		
CD40L+/IL2-/TNFa+/IFNg-, D7 (N=4;3;13;15;26;28)	4 (4 to 4)	4 (4 to 4)		
CD40L+/IL2-/TNFa+/IFNg-, D30 (N=5;2;16;16;34;34)	4 (4 to 4)	4 (4 to 4)		
CD40L+/IL2-/TNFa+/IFNg-, D37 (N=5;3;18;19;34;34)	4 (4 to 4)	4 (4 to 4)		
CD40L+/IL2-/TNFa+/IFNg-, D60 (N=4;2;15;18;31;32)	4 (4 to 4)	4 (4 to 4)		
CD40L+/IL2-/TNFa+/IFNg-, D210 (N=6;3;13;17;37;36)	4 (4 to 19)	4 (4 to 9)		

## Statistical analyses

No statistical analyses for this end point

## Secondary: Frequency of M72-specific CD8+ T cells per million cells expressing any combination of immune markers.

End point title	Frequency of M72-specific CD8+ T cells per million cells expressing any combination of immune markers.
-----------------	--

End point description:

Immune markers expressed were among Interleukin-2 (IL-2), Interferon-gamma (IFN-g), Tumour necrosis factor-alpha (TNF-a) and/or CD40-ligand (CD40-L).

End point type Secondary

End point timeframe:

Prior to dose 1 (Day 0 - PRE), post-dose 1 (Days 7 - D7 and 30 - D30), post-dose 2 (Days 37 - D37, 60 - D60 and 210 - D210)

End point values	TB Treatment GSK 692342 Group	TB Treatment Saline Group	TB Treated GSK 692342 Group	TB Treated Saline Group
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	6	3	18	22
Units: T cells/million cells				
median (inter-quartile range (Q1-Q3))				
CD40L+/IL2-/TNFa-/IFNg+, PRE (N=4;3;15;22;30;30)	4 (4 to 23.5)	4 (4 to 26)	4 (4 to 5)	4 (4 to 4)
CD40L+/IL2-/TNFa-/IFNg+, D7 (N=4;3;13;15;26;28)	4 (4 to 4)	4 (4 to 4)	4 (4 to 54)	4 (4 to 22)
CD40L+/IL2-/TNFa-/IFNg+, D30 (N=5;2;16;16;34;34)	4 (4 to 4)	41.5 (4 to 79)	4 (4 to 4)	4 (4 to 28.5)
CD40L+/IL2-/TNFa-/IFNg+, D37 (N=5;3;18;19;34;34)	4 (4 to 4)	4 (4 to 36)	4 (4 to 4)	4 (4 to 4)
CD40L+/IL2-/TNFa-/IFNg+, D60 (N=4;2;15;18;31;32)	4 (4 to 21)	16.5 (4 to 29)	4 (4 to 4)	14.5 (4 to 46)
CD40L+/IL2-/TNFa-/IFNg+, D210 (N=6;3;13;17;37;36)	19.5 (4 to 88)	4 (4 to 4)	4 (4 to 35)	4 (4 to 4)
CD40L+/IL2-/TNFa-/IFNg-, PRE (N=4;3;15;22;30;30)	97.5 (4 to 412)	143 (4 to 178)	29 (4 to 203)	4 (4 to 139)
CD40L+/IL2-/TNFa-/IFNg-, D7 (N=4;3;13;15;26;28)	33.5 (4 to 68)	110 (93 to 390)	4 (4 to 4)	4 (4 to 413)
CD40L+/IL2-/TNFa-/IFNg-, D30 (N=5;2;16;16;34;34)	73 (4 to 113)	161 (83 to 239)	4 (4 to 23)	4 (4 to 78.5)
CD40L+/IL2-/TNFa-/IFNg-, D37 (N=5;3;18;19;34;34)	4 (4 to 203)	4 (4 to 216)	4 (4 to 293)	43 (4 to 125)
CD40L+/IL2-/TNFa-/IFNg-, D60 (N=4;2;15;18;31;32)	18.5 (4 to 163.5)	44.5 (4 to 85)	101 (4 to 345)	85 (4 to 270)
CD40L+/IL2-/TNFa-/IFNg-, D210 (N=6;3;13;17;37;36)	53 (15 to 92)	122 (4 to 202)	333 (4 to 583)	121 (4 to 249)

End point values	TB Naive GSK 692342 Group	TB Naive Saline Group		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	37	36		
Units: T cells/million cells				
median (inter-quartile range (Q1-Q3))				
CD40L+/IL2-/TNFa-/IFNg+, PRE (N=4;3;15;22;30;30)	4 (4 to 26)	4 (4 to 18)		
CD40L+/IL2-/TNFa-/IFNg+, D7 (N=4;3;13;15;26;28)	4 (4 to 24)	4 (4 to 4.5)		
CD40L+/IL2-/TNFa-/IFNg+, D30 (N=5;2;16;16;34;34)	4 (4 to 25)	4 (4 to 31)		

CD40L+/IL2-/TNFa-/IFNg+, D37 (N=5;3;18;19;34;34)	4 (4 to 21)	4 (4 to 23)		
CD40L+/IL2-/TNFa-/IFNg+, D60 (N=4;2;15;18;31;32)	4 (4 to 76)	4 (4 to 14.5)		
CD40L+/IL2-/TNFa-/IFNg+, D210 (N=6;3;13;17;37;36)	4 (4 to 29)	4 (4 to 34.5)		
CD40L+/IL2-/TNFa-/IFNg-, PRE (N=4;3;15;22;30;30)	7.5 (4 to 130)	25 (4 to 222)		
CD40L+/IL2-/TNFa-/IFNg-, D7 (N=4;3;13;15;26;28)	4 (4 to 183)	26 (4 to 164)		
CD40L+/IL2-/TNFa-/IFNg-, D30 (N=5;2;16;16;34;34)	4 (4 to 71)	99.5 (4 to 288)		
CD40L+/IL2-/TNFa-/IFNg-, D37 (N=5;3;18;19;34;34)	4 (4 to 127)	13.5 (4 to 213)		
CD40L+/IL2-/TNFa-/IFNg-, D60 (N=4;2;15;18;31;32)	61 (4 to 153)	36.5 (4 to 214)		
CD40L+/IL2-/TNFa-/IFNg-, D210 (N=6;3;13;17;37;36)	22 (4 to 311)	33.5 (4 to 302.5)		

## Statistical analyses

No statistical analyses for this end point

## Secondary: Frequency of M72-specific CD8+ T cells per million cells expressing any combination of immune markers.

End point title	Frequency of M72-specific CD8+ T cells per million cells expressing any combination of immune markers.
End point description: Immune markers expressed were among Interleukin-2 (IL-2), Interferon-gamma (IFN-g), Tumour necrosis factor-alpha (TNF-a) and/or CD40-ligand (CD40-L).	
End point type	Secondary
End point timeframe: Prior to dose 1 (Day 0 - PRE), post-dose 1 (Days 7 - D7 and 30 - D30), post-dose 2 (Days 37 - D37, 60 - D60 and 210 - D210)	

End point values	TB Treatment GSK 692342 Group	TB Treatment Saline Group	TB Treated GSK 692342 Group	TB Treated Saline Group
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	6	3	18	22
Units: T cells/million cells				
median (inter-quartile range (Q1-Q3))				
CD40L-/IL2+/TNFa+/IFNg+, PRE (N=4;3;15;22;30;30)	4 (4 to 4)	4 (4 to 4)	4 (4 to 4)	4 (4 to 4)
CD40L-/IL2+/TNFa+/IFNg+, D7 (N=4;3;13;15;26;28)	4 (4 to 4)	4 (4 to 4)	4 (4 to 4)	4 (4 to 4)
CD40L-/IL2+/TNFa+/IFNg+, D30 (N=5;2;16;16;34;34)	4 (4 to 4)	4 (4 to 4)	4 (4 to 4)	4 (4 to 4)
CD40L-/IL2+/TNFa+/IFNg+, D37 (N=5;3;18;19;34;34)	4 (4 to 4)	4 (4 to 4)	4 (4 to 4)	4 (4 to 4)
CD40L-/IL2+/TNFa+/IFNg+, D60 (N=4;2;15;18;31;32)	4 (4 to 4)	4 (4 to 4)	4 (4 to 4)	4 (4 to 4)

CD40L-/IL2+/TNFa+/IFNg+, D210 (N=6;3;13;17;37;36)	4 (4 to 4)	4 (4 to 4)	4 (4 to 4)	4 (4 to 4)
CD40L-/IL2+/TNFa+/IFNg-, PRE (N=4;3;15;22;30;30)	4 (4 to 4)	4 (4 to 4)	4 (4 to 4)	4 (4 to 4)
CD40L-/IL2+/TNFa+/IFNg-, D7 (N=4;3;13;15;26;28)	4 (4 to 4)	4 (4 to 4)	4 (4 to 4)	4 (4 to 4)
CD40L-/IL2+/TNFa+/IFNg-, D30 (N=5;2;16;16;34;34)	4 (4 to 4)	4 (4 to 4)	4 (4 to 4)	4 (4 to 4)
CD40L-/IL2+/TNFa+/IFNg-, D37 (N=5;3;18;19;34;34)	4 (4 to 4)	4 (4 to 4)	4 (4 to 4)	4 (4 to 4)
CD40L-/IL2+/TNFa+/IFNg-, D60 (N=4;2;15;18;31;32)	4 (4 to 15.5)	4 (4 to 4)	4 (4 to 4)	4 (4 to 4)
CD40L-/IL2+/TNFa+/IFNg-, D210 (N=6;3;13;17;37;36)	4 (4 to 4)	4 (4 to 4)	4 (4 to 4)	4 (4 to 4)

End point values	TB Naive GSK 692342 Group	TB Naive Saline Group		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	37	36		
Units: T cells/million cells				
median (inter-quartile range (Q1-Q3))				
CD40L-/IL2+/TNFa+/IFNg+, PRE (N=4;3;15;22;30;30)	4 (4 to 4)	4 (4 to 4)		
CD40L-/IL2+/TNFa+/IFNg+, D7 (N=4;3;13;15;26;28)	4 (4 to 4)	4 (4 to 4)		
CD40L-/IL2+/TNFa+/IFNg+, D30 (N=5;2;16;16;34;34)	4 (4 to 4)	4 (4 to 4)		
CD40L-/IL2+/TNFa+/IFNg+, D37 (N=5;3;18;19;34;34)	4 (4 to 4)	4 (4 to 4)		
CD40L-/IL2+/TNFa+/IFNg+, D60 (N=4;2;15;18;31;32)	4 (4 to 4)	4 (4 to 4)		
CD40L-/IL2+/TNFa+/IFNg+, D210 (N=6;3;13;17;37;36)	4 (4 to 4)	4 (4 to 4)		
CD40L-/IL2+/TNFa+/IFNg-, PRE (N=4;3;15;22;30;30)	4 (4 to 4)	4 (4 to 4)		
CD40L-/IL2+/TNFa+/IFNg-, D7 (N=4;3;13;15;26;28)	4 (4 to 4)	4 (4 to 4)		
CD40L-/IL2+/TNFa+/IFNg-, D30 (N=5;2;16;16;34;34)	4 (4 to 4)	4 (4 to 4)		
CD40L-/IL2+/TNFa+/IFNg-, D37 (N=5;3;18;19;34;34)	4 (4 to 4)	4 (4 to 4)		
CD40L-/IL2+/TNFa+/IFNg-, D60 (N=4;2;15;18;31;32)	4 (4 to 4)	4 (4 to 4)		
CD40L-/IL2+/TNFa+/IFNg-, D210 (N=6;3;13;17;37;36)	4 (4 to 4)	4 (4 to 4)		

## Statistical analyses

No statistical analyses for this end point

## Secondary: Frequency of M72-specific CD8+ T cells per million cells expressing any combination of immune markers.

End point title	Frequency of M72-specific CD8+ T cells per million cells expressing any combination of immune markers.
-----------------	--

End point description:

Immune markers expressed were among Interleukin-2 (IL-2), Interferon-gamma (IFN-g), Tumour necrosis factor-alpha (TNF-a) and/or CD40-ligand (CD40-L).

End point type Secondary

End point timeframe:

Prior to dose 1 (Day 0 - PRE), post-dose 1 (Days 7 - D7 and 30 - D30), post-dose 2 (Days 37 - D37, 60 - D60 and 210 - D210)

End point values	TB Treatment GSK 692342 Group	TB Treatment Saline Group	TB Treated GSK 692342 Group	TB Treated Saline Group
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	6	3	18	22
Units: T cells/million cells				
median (inter-quartile range (Q1-Q3))				
CD40L-/IL2+/TNFa-/IFNg+, PRE (N=4;3;15;22;30;30)	4 (4 to 4)	4 (4 to 4)	4 (4 to 4)	4 (4 to 4)
CD40L-/IL2+/TNFa-/IFNg+, D7 (N=4;3;13;15;26;28)	4 (4 to 4)	4 (4 to 4)	4 (4 to 4)	4 (4 to 4)
CD40L-/IL2+/TNFa-/IFNg+, D30 (N=5;2;16;16;34;34)	4 (4 to 4)	4 (4 to 4)	4 (4 to 4)	4 (4 to 4)
CD40L-/IL2+/TNFa-/IFNg+, D37 (N=5;3;18;19;34;34)	4 (4 to 4)	4 (4 to 4)	4 (4 to 4)	4 (4 to 4)
CD40L-/IL2+/TNFa-/IFNg+, D60 (N=4;2;15;18;31;32)	4 (4 to 4)	4 (4 to 4)	4 (4 to 4)	4 (4 to 4)
CD40L-/IL2+/TNFa-/IFNg+, D210 (N=6;3;13;17;37;36)	4 (4 to 4)	4 (4 to 4)	4 (4 to 4)	4 (4 to 4)
CD40L-/IL2+/TNFa-/IFNg-, PRE (N=4;3;15;22;30;30)	4 (4 to 4)	4 (4 to 4)	4 (4 to 41)	4 (4 to 4)
CD40L-/IL2+/TNFa-/IFNg-, D7 (N=4;3;13;15;26;28)	4 (4 to 4)	4 (4 to 37)	4 (4 to 4)	4 (4 to 4)
CD40L-/IL2+/TNFa-/IFNg-, D30 (N=5;2;16;16;34;34)	4 (4 to 4)	4 (4 to 4)	4 (4 to 32)	4 (4 to 4)
CD40L-/IL2+/TNFa-/IFNg-, D37 (N=5;3;18;19;34;34)	28 (4 to 49)	4 (4 to 4)	4 (4 to 6)	4 (4 to 4)
CD40L-/IL2+/TNFa-/IFNg-, D60 (N=4;2;15;18;31;32)	4 (4 to 15.5)	4 (4 to 4)	4 (4 to 4)	4 (4 to 4)
CD40L-/IL2+/TNFa-/IFNg-, D210 (N=6;3;13;17;37;36)	4 (4 to 13)	38 (4 to 98)	4 (4 to 4)	4 (4 to 4)

End point values	TB Naive GSK 692342 Group	TB Naive Saline Group		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	37	36		
Units: T cells/million cells				
median (inter-quartile range (Q1-Q3))				
CD40L-/IL2+/TNFa-/IFNg+, PRE (N=4;3;15;22;30;30)	4 (4 to 4)	4 (4 to 4)		
CD40L-/IL2+/TNFa-/IFNg+, D7 (N=4;3;13;15;26;28)	4 (4 to 4)	4 (4 to 4)		
CD40L-/IL2+/TNFa-/IFNg+, D30 (N=5;2;16;16;34;34)	4 (4 to 4)	4 (4 to 4)		

CD40L-/IL2+/TNFa-/IFNg+, D37 (N=5;3;18;19;34;34)	4 (4 to 4)	4 (4 to 4)		
CD40L-/IL2+/TNFa-/IFNg+, D60 (N=4;2;15;18;31;32)	4 (4 to 4)	4 (4 to 4)		
CD40L-/IL2+/TNFa-/IFNg+, D210 (N=6;3;13;17;37;36)	4 (4 to 4)	4 (4 to 4)		
CD40L-/IL2+/TNFa-/IFNg-, PRE (N=4;3;15;22;30;30)	4 (4 to 4)	4 (4 to 5)		
CD40L-/IL2+/TNFa-/IFNg-, D7 (N=4;3;13;15;26;28)	4 (4 to 20)	4 (4 to 23.5)		
CD40L-/IL2+/TNFa-/IFNg-, D30 (N=5;2;16;16;34;34)	4 (4 to 19)	4 (4 to 4)		
CD40L-/IL2+/TNFa-/IFNg-, D37 (N=5;3;18;19;34;34)	4 (4 to 18)	4 (4 to 28)		
CD40L-/IL2+/TNFa-/IFNg-, D60 (N=4;2;15;18;31;32)	4 (4 to 20)	4 (4 to 19)		
CD40L-/IL2+/TNFa-/IFNg-, D210 (N=6;3;13;17;37;36)	4 (4 to 4)	4 (4 to 19)		

## Statistical analyses

No statistical analyses for this end point

## Secondary: Frequency of M72-specific CD8+ T cells per million cells expressing any combination of immune markers.

End point title	Frequency of M72-specific CD8+ T cells per million cells expressing any combination of immune markers.
End point description: Immune markers expressed were among Interleukin-2 (IL-2), Interferon-gamma (IFN-g), Tumour necrosis factor-alpha (TNF-a) and/or CD40-ligand (CD40-L).	
End point type	Secondary
End point timeframe: Prior to dose 1 (Day 0 - PRE), post-dose 1 (Days 7 - D7 and 30 - D30), post-dose 2 (Days 37 - D37, 60 - D60 and 210 - D210)	

End point values	TB Treatment GSK 692342 Group	TB Treatment Saline Group	TB Treated GSK 692342 Group	TB Treated Saline Group
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	6	3	18	22
Units: T cells/million cells				
median (inter-quartile range (Q1-Q3))				
CD40L-/IL2-/TNFa+/IFNg+, PRE (N=4;3;15;22;30;30)	4 (4 to 199.5)	4 (4 to 73)	4 (4 to 47)	30 (4 to 286)
CD40L-/IL2-/TNFa+/IFNg+, D7 (N=4;3;13;15;26;28)	50 (30.5 to 101)	4 (4 to 5)	32 (4 to 109)	4 (4 to 284)
CD40L-/IL2-/TNFa+/IFNg+, D30 (N=5;2;16;16;34;34)	4 (4 to 4)	4 (4 to 4)	4 (4 to 107)	91.5 (4 to 1024)
CD40L-/IL2-/TNFa+/IFNg+, D37 (N=5;3;18;19;34;34)	41 (4 to 66)	4 (4 to 53)	28.5 (4 to 285)	28 (4 to 228)
CD40L-/IL2-/TNFa+/IFNg+, D60 (N=4;2;15;18;31;32)	19 (4 to 144)	35 (4 to 66)	29 (4 to 149)	58 (4 to 432)



CD40L-/IL2-/TNFa+/IFNg+, D210 (N=6;3;13;17;37;36)	51 (4 to 264)	4 (4 to 4)	4 (4 to 184)	4 (4 to 101)
CD40L-/IL2-/TNFa+/IFNg-, PRE (N=4;3;15;22;30;30)	21 (4 to 80)	4 (4 to 61)	4 (4 to 36)	7.5 (4 to 37)
CD40L-/IL2-/TNFa+/IFNg-, D7 (N=4;3;13;15;26;28)	17 (4 to 61)	4 (4 to 5)	4 (4 to 59)	4 (4 to 82)
CD40L-/IL2-/TNFa+/IFNg-, D30 (N=5;2;16;16;34;34)	4 (4 to 4)	80 (4 to 156)	4 (4 to 67.5)	47.5 (6 to 123)
CD40L-/IL2-/TNFa+/IFNg-, D37 (N=5;3;18;19;34;34)	40 (4 to 128)	4 (4 to 69)	36.5 (4 to 112)	4 (4 to 43)
CD40L-/IL2-/TNFa+/IFNg-, D60 (N=4;2;15;18;31;32)	16 (4 to 54)	4 (4 to 4)	4 (4 to 89)	18.5 (4 to 90)
CD40L-/IL2-/TNFa+/IFNg-, D210 (N=6;3;13;17;37;36)	4 (4 to 4)	4 (4 to 8)	4 (4 to 4)	4 (4 to 42)

End point values	TB Naive GSK 692342 Group	TB Naive Saline Group		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	37	36		
Units: T cells/million cells				
median (inter-quartile range (Q1-Q3))				
CD40L-/IL2-/TNFa+/IFNg+, PRE (N=4;3;15;22;30;30)	4 (4 to 37)	4 (4 to 45)		
CD40L-/IL2-/TNFa+/IFNg+, D7 (N=4;3;13;15;26;28)	4 (4 to 104)	9 (4 to 102)		
CD40L-/IL2-/TNFa+/IFNg+, D30 (N=5;2;16;16;34;34)	4 (4 to 39)	4 (4 to 73)		
CD40L-/IL2-/TNFa+/IFNg+, D37 (N=5;3;18;19;34;34)	4 (4 to 30)	4 (4 to 85)		
CD40L-/IL2-/TNFa+/IFNg+, D60 (N=4;2;15;18;31;32)	4 (4 to 39)	4 (4 to 45)		
CD40L-/IL2-/TNFa+/IFNg+, D210 (N=6;3;13;17;37;36)	4 (4 to 27)	4 (4 to 30.5)		
CD40L-/IL2-/TNFa+/IFNg-, PRE (N=4;3;15;22;30;30)	25.5 (4 to 57)	4 (4 to 18)		
CD40L-/IL2-/TNFa+/IFNg-, D7 (N=4;3;13;15;26;28)	20.5 (4 to 39)	4 (4 to 27)		
CD40L-/IL2-/TNFa+/IFNg-, D30 (N=5;2;16;16;34;34)	20.5 (4 to 67)	24.5 (4 to 71)		
CD40L-/IL2-/TNFa+/IFNg-, D37 (N=5;3;18;19;34;34)	4 (4 to 27)	5 (4 to 64)		
CD40L-/IL2-/TNFa+/IFNg-, D60 (N=4;2;15;18;31;32)	20 (4 to 56)	4.5 (4 to 30)		
CD40L-/IL2-/TNFa+/IFNg-, D210 (N=6;3;13;17;37;36)	4 (4 to 60)	4 (4 to 29)		

## Statistical analyses

No statistical analyses for this end point

## Secondary: Frequency of M72-specific CD8+ T cells per million cells expressing any combination of immune markers.

End point title	Frequency of M72-specific CD8+ T cells per million cells expressing any combination of immune markers.
-----------------	--

End point description:

Immune markers expressed were among Interleukin-2 (IL-2), Interferon-gamma (IFN-g), Tumour necrosis factor-alpha (TNF-a) and/or CD40-ligand (CD40-L).

End point type	Secondary
----------------	-----------

End point timeframe:

Prior to dose 1 (Day 0 - PRE), post-dose 1 (Days 7 - D7 and 30 - D30), post-dose 2 (Days 37 - D37, 60 - D60 and 210 - D210)

End point values	TB Treatment GSK 692342 Group	TB Treatment Saline Group	TB Treated GSK 692342 Group	TB Treated Saline Group
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	6	3	18	22
Units: T cells/million cells				
median (inter-quartile range (Q1-Q3))				
CD40L-/IL2-/TNFa-/IFNg+, PRE (N=4;3;15;22;30;30)	54.5 (25.5 to 821)	6 (4 to 95)	70 (12 to 541)	216.5 (57 to 1831)
CD40L-/IL2-/TNFa-/IFNg+, D7 (N=4;3;13;15;26;28)	89 (36.5 to 893.5)	9 (4 to 31)	152 (4 to 575)	205 (90 to 1660)
CD40L-/IL2-/TNFa-/IFNg+, D30 (N=5;2;16;16;34;34)	96 (26 to 163)	118 (4 to 232)	127.5 (13 to 327.5)	386.5 (27 to 1969.5)
CD40L-/IL2-/TNFa-/IFNg+, D37 (N=5;3;18;19;34;34)	48 (4 to 78)	33 (4 to 81)	100.5 (48 to 326)	229 (4 to 1022)
CD40L-/IL2-/TNFa-/IFNg+, D60 (N=4;2;15;18;31;32)	147.5 (55 to 824.5)	4 (4 to 4)	70 (4 to 1116)	172 (18 to 1492)
CD40L-/IL2-/TNFa-/IFNg+, D210 (N=6;3;13;17;37;36)	286.5 (48 to 469)	4 (4 to 59)	51 (4 to 245)	85 (4 to 628)

End point values	TB Naive GSK 692342 Group	TB Naive Saline Group		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	37	36		
Units: T cells/million cells				
median (inter-quartile range (Q1-Q3))				
CD40L-/IL2-/TNFa-/IFNg+, PRE (N=4;3;15;22;30;30)	54.5 (4 to 159)	78.5 (25 to 349)		
CD40L-/IL2-/TNFa-/IFNg+, D7 (N=4;3;13;15;26;28)	69.5 (43 to 830)	90.5 (4.5 to 484.5)		
CD40L-/IL2-/TNFa-/IFNg+, D30 (N=5;2;16;16;34;34)	64.5 (4 to 438)	151.5 (28 to 467)		
CD40L-/IL2-/TNFa-/IFNg+, D37 (N=5;3;18;19;34;34)	46.5 (4 to 179)	83.5 (4 to 335)		
CD40L-/IL2-/TNFa-/IFNg+, D60 (N=4;2;15;18;31;32)	13 (4 to 65)	59 (4 to 310)		
CD40L-/IL2-/TNFa-/IFNg+, D210 (N=6;3;13;17;37;36)	69 (4 to 233)	60 (22 to 232.5)		

## Statistical analyses



## Adverse events

### Adverse events information

Timeframe for reporting adverse events:

Solicited symptoms: During the 7 day (Days 0-6), after each vaccine dose, unsolicited AEs: During the 30 day (Days 0-29) after vaccination, SAEs: Up to day 210

Adverse event reporting additional description:

Results presented per group consist of a summary of the events (SAEs and AEs other than SAEs, respectively) reported, compiling overall number of subjects with events across the different periods of assessment.

Assessment type	Systematic
-----------------	------------

### Dictionary used

Dictionary name	MedDRA
-----------------	--------

Dictionary version	18.0
--------------------	------

### Reporting groups

Reporting group title	TB Treatment GSK 692342 Group
-----------------------	-------------------------------

Reporting group description:

Subjects having completed the intensive phase of treatment, i.e. 2 to 4 months post initiation of treatment, who received the GSK 692342 vaccine according to a 2-dose schedule at Months 0 and 1.

Reporting group title	TB Treatment Saline Group
-----------------------	---------------------------

Reporting group description:

Subjects having completed the intensive phase of treatment, i.e. 2 to 4 months post initiation of treatment who received a placebo (physiological saline) according to a 2-dose schedule at Months 0 and 1.

Reporting group title	TB Treated GSK 692342 Group
-----------------------	-----------------------------

Reporting group description:

Subjects having successfully completed treatment for TB disease at least 1 year prior to the study, who during this study received the GSK 692342 vaccine according to a 2-dose schedule at Months 0 and 1.

Reporting group title	TB Treated Saline Group
-----------------------	-------------------------

Reporting group description:

Subjects having successfully completed treatment for TB disease at least 1 year prior to the study, who in this study received a placebo (physiological saline) according to a 2-dose schedule at Months 0 and 1.

Reporting group title	TB Naive GSK 692342 Group
-----------------------	---------------------------

Reporting group description:

Subjects unaffected by tuberculosis who received the GSK 692342 vaccine according to a 2-dose schedule at Months 0 and 1.

Reporting group title	TB Naive Saline Group
-----------------------	-----------------------

Reporting group description:

Subjects unaffected by tuberculosis who received a placebo (physiological saline) according to a 2-dose schedule at Months 0 and 1.

Serious adverse events	TB Treatment GSK 692342 Group	TB Treatment Saline Group	TB Treated GSK 692342 Group
Total subjects affected by serious adverse events			
subjects affected / exposed	0 / 7 (0.00%)	0 / 6 (0.00%)	2 / 24 (8.33%)
number of deaths (all causes)	0	0	0
number of deaths resulting from adverse events	0	0	0
Immune system disorders			
Hypersensitivity			

alternative assessment type: Non-systematic			
subjects affected / exposed	0 / 7 (0.00%)	0 / 6 (0.00%)	1 / 24 (4.17%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal disorders			
Anal fistula			
alternative assessment type: Non-systematic			
subjects affected / exposed	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 24 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Haemorrhoids			
alternative assessment type: Non-systematic			
subjects affected / exposed	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 24 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal and urinary disorders			
Calculus ureteric			
alternative assessment type: Non-systematic			
subjects affected / exposed	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 24 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Calculus urinary			
alternative assessment type: Non-systematic			
subjects affected / exposed	0 / 7 (0.00%)	0 / 6 (0.00%)	1 / 24 (4.17%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hydronephrosis			
alternative assessment type: Non-systematic			
subjects affected / exposed	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 24 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infections and infestations			
Pneumonia			
alternative assessment type: Non-systematic			

subjects affected / exposed	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 24 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

<b>Serious adverse events</b>	TB Treated Saline Group	TB Naive GSK 692342 Group	TB Naive Saline Group
Total subjects affected by serious adverse events			
subjects affected / exposed	2 / 25 (8.00%)	1 / 40 (2.50%)	0 / 40 (0.00%)
number of deaths (all causes)	0	0	0
number of deaths resulting from adverse events	0	0	0
Immune system disorders			
Hypersensitivity			
alternative assessment type: Non-systematic			
subjects affected / exposed	0 / 25 (0.00%)	0 / 40 (0.00%)	0 / 40 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal disorders			
Anal fistula			
alternative assessment type: Non-systematic			
subjects affected / exposed	0 / 25 (0.00%)	1 / 40 (2.50%)	0 / 40 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Haemorrhoids			
alternative assessment type: Non-systematic			
subjects affected / exposed	0 / 25 (0.00%)	1 / 40 (2.50%)	0 / 40 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal and urinary disorders			
Calculus ureteric			
alternative assessment type: Non-systematic			
subjects affected / exposed	1 / 25 (4.00%)	0 / 40 (0.00%)	0 / 40 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Calculus urinary			
alternative assessment type: Non-systematic			

subjects affected / exposed	0 / 25 (0.00%)	0 / 40 (0.00%)	0 / 40 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hydronephrosis			
alternative assessment type: Non-systematic			
subjects affected / exposed	1 / 25 (4.00%)	0 / 40 (0.00%)	0 / 40 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infections and infestations			
Pneumonia			
alternative assessment type: Non-systematic			
subjects affected / exposed	1 / 25 (4.00%)	0 / 40 (0.00%)	0 / 40 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Frequency threshold for reporting non-serious adverse events: 5 %

<b>Non-serious adverse events</b>	TB Treatment GSK 692342 Group	TB Treatment Saline Group	TB Treated GSK 692342 Group
Total subjects affected by non-serious adverse events			
subjects affected / exposed	6 / 7 (85.71%)	2 / 6 (33.33%)	22 / 24 (91.67%)
Investigations			
Hepatic enzyme increased			
alternative assessment type: Non-systematic			
subjects affected / exposed	0 / 7 (0.00%)	0 / 6 (0.00%)	2 / 24 (8.33%)
occurrences (all)	0	0	2
Nervous system disorders			
Headache			
alternative assessment type: Non-systematic			
subjects affected / exposed	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 24 (0.00%)
occurrences (all)	0	0	0
General disorders and administration site conditions			
Pain			
subjects affected / exposed	6 / 7 (85.71%)	1 / 6 (16.67%)	22 / 24 (91.67%)
occurrences (all)	6	1	22
Redness			

subjects affected / exposed occurrences (all)	3 / 7 (42.86%) 3	0 / 6 (0.00%) 0	8 / 24 (33.33%) 8
Swelling subjects affected / exposed occurrences (all)	3 / 7 (42.86%) 3	0 / 6 (0.00%) 0	6 / 24 (25.00%) 6
Fatigue subjects affected / exposed occurrences (all)	3 / 7 (42.86%) 3	2 / 6 (33.33%) 2	17 / 24 (70.83%) 17
Gastrointestinal symptoms subjects affected / exposed occurrences (all)	2 / 7 (28.57%) 2	0 / 6 (0.00%) 0	10 / 24 (41.67%) 10
Headache (solicited) subjects affected / exposed occurrences (all)	3 / 7 (42.86%) 3	1 / 6 (16.67%) 1	18 / 24 (75.00%) 18
Malaise subjects affected / exposed occurrences (all)	3 / 7 (42.86%) 3	2 / 6 (33.33%) 2	16 / 24 (66.67%) 16
Myalgia subjects affected / exposed occurrences (all)	3 / 7 (42.86%) 3	1 / 6 (16.67%) 1	18 / 24 (75.00%) 18
Temperature/(Axillary) subjects affected / exposed occurrences (all)	4 / 7 (57.14%) 4	1 / 6 (16.67%) 1	10 / 24 (41.67%) 10
Musculoskeletal and connective tissue disorders Arthralgia alternative assessment type: Non-systematic subjects affected / exposed occurrences (all)	0 / 7 (0.00%) 0	0 / 6 (0.00%) 0	3 / 24 (12.50%) 3
Infections and infestations Upper respiratory tract infection alternative assessment type: Non-systematic subjects affected / exposed occurrences (all)  Gastroenteritis alternative assessment type: Non-systematic	0 / 7 (0.00%) 0	0 / 6 (0.00%) 0	3 / 24 (12.50%) 3



subjects affected / exposed	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 24 (0.00%)
occurrences (all)	0	0	0
Nasopharyngitis			
alternative assessment type: Non-systematic			
subjects affected / exposed	0 / 7 (0.00%)	0 / 6 (0.00%)	2 / 24 (8.33%)
occurrences (all)	0	0	2
Urinary tract infection			
alternative assessment type: Non-systematic			
subjects affected / exposed	0 / 7 (0.00%)	0 / 6 (0.00%)	2 / 24 (8.33%)
occurrences (all)	0	0	2

<b>Non-serious adverse events</b>	TB Treated Saline Group	TB Naive GSK 692342 Group	TB Naive Saline Group
Total subjects affected by non-serious adverse events			
subjects affected / exposed	8 / 25 (32.00%)	39 / 40 (97.50%)	10 / 40 (25.00%)
Investigations			
Hepatic enzyme increased			
alternative assessment type: Non-systematic			
subjects affected / exposed	0 / 25 (0.00%)	0 / 40 (0.00%)	0 / 40 (0.00%)
occurrences (all)	0	0	0
Nervous system disorders			
Headache			
alternative assessment type: Non-systematic			
subjects affected / exposed	0 / 25 (0.00%)	2 / 40 (5.00%)	0 / 40 (0.00%)
occurrences (all)	0	2	0
General disorders and administration site conditions			
Pain			
subjects affected / exposed	3 / 25 (12.00%)	39 / 40 (97.50%)	8 / 40 (20.00%)
occurrences (all)	3	39	8
Redness			
subjects affected / exposed	0 / 25 (0.00%)	10 / 40 (25.00%)	0 / 40 (0.00%)
occurrences (all)	0	10	0
Swelling			
subjects affected / exposed	1 / 25 (4.00%)	11 / 40 (27.50%)	0 / 40 (0.00%)
occurrences (all)	1	11	0
Fatigue			

subjects affected / exposed occurrences (all)	8 / 25 (32.00%) 8	36 / 40 (90.00%) 36	10 / 40 (25.00%) 10
Gastrointestinal symptoms subjects affected / exposed occurrences (all)	4 / 25 (16.00%) 4	16 / 40 (40.00%) 16	6 / 40 (15.00%) 6
Headache (solicited) subjects affected / exposed occurrences (all)	4 / 25 (16.00%) 4	24 / 40 (60.00%) 24	6 / 40 (15.00%) 6
Malaise subjects affected / exposed occurrences (all)	6 / 25 (24.00%) 6	35 / 40 (87.50%) 35	9 / 40 (22.50%) 9
Myalgia subjects affected / exposed occurrences (all)	5 / 25 (20.00%) 5	34 / 40 (85.00%) 34	7 / 40 (17.50%) 7
Temperature/(Axillary) subjects affected / exposed occurrences (all)	0 / 25 (0.00%) 0	17 / 40 (42.50%) 17	0 / 40 (0.00%) 0
Musculoskeletal and connective tissue disorders Arthralgia alternative assessment type: Non-systematic subjects affected / exposed occurrences (all)	0 / 25 (0.00%) 0	0 / 40 (0.00%) 0	0 / 40 (0.00%) 0
Infections and infestations Upper respiratory tract infection alternative assessment type: Non-systematic subjects affected / exposed occurrences (all)	0 / 25 (0.00%) 0	4 / 40 (10.00%) 4	3 / 40 (7.50%) 3
Gastroenteritis alternative assessment type: Non-systematic subjects affected / exposed occurrences (all)	0 / 25 (0.00%) 0	2 / 40 (5.00%) 2	1 / 40 (2.50%) 1
Nasopharyngitis alternative assessment type: Non-systematic subjects affected / exposed occurrences (all)	0 / 25 (0.00%) 0	1 / 40 (2.50%) 1	0 / 40 (0.00%) 0

Urinary tract infection			
alternative assessment type: Non-systematic			
subjects affected / exposed	0 / 25 (0.00%)	0 / 40 (0.00%)	0 / 40 (0.00%)
occurrences (all)	0	0	0

## More information

### Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

Date	Amendment
14 May 2012	<ul style="list-style-type: none"><li>At the European Medicines Agency's (EMA) request, GSK Biologicals has updated its procedure for emergency unblinding during the conduct of a clinical study. According to the revised procedure, the responsibility and the decision to break the treatment code in emergency situations resides solely with the investigator and consequently, the investigator will have full authority to break the treatment code.</li><li>Change in the number of participating countries in this study.</li><li>It has been clarified that TB treatment for subjects belonging to the TB-treatment cohort will be provided independent of this study.</li><li>Additional minor modifications have been implemented.</li></ul>
18 February 2013	This amendment aims to correct the centre-specific information provided in the protocol. However, as centre-specific information is available in other documents included in the clinical trial application, it was decided to remove centre-specific information from the protocol to avoid future amendments in case enrolment of subjects in the TB treated and TB treatment cohorts remains difficult and additional centres/countries might need to be added to the study.
16 January 2014	Due to a safety signal identified in the TB treatment cohort (increased local solicited symptoms post-dose 2), the protocol was amended to include exploratory testing on blood samples taken at Days 0, 7, 30, 37, 60 and 210.

Notes:

### Interruptions (globally)

Were there any global interruptions to the trial? Yes

Date	Interruption	Restart date
10 April 2014	A safety signal was observed during a planned interim safety review. In consequence the trial was put on hold. After careful consideration further conduct of this safety study is not considered the best course of action and enrolment in the study was terminated.	-

Notes:

### Limitations and caveats

None reported